SIGA (SIGA) 10-K 10 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information Document (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 14, 2014	Jun. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'SIGA TECHNOLOGIES INC	'	'
Entity Central Index Key	'0001010086	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Accelerated Filer	'	'
Trading Symbol	'SIGA	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Amendment Flag	'false	'	'
Entity Common Stock, Shares Outstanding	'	53,262,322	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Public Float	'	'	$148,806,051

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
ASSETS	'	'
Cash and cash equivalents	$91,309,754	$32,017,490
Accounts receivable	982,023	970,288
Inventory	20,515,349	17,641,922
Prepaid expense and other assets, current	750,808	801,149
Deferred tax assets	10,383,908	33,515,327
Total current assets	123,941,842	84,946,176
Property, plant and equipment, net	1,382,073	987,869
Accounts receivable	0	3,771,219
Deferred costs	22,583,202	2,841,534
Goodwill	898,334	898,334
Other assets	2,078,159	2,181,720
Deferred tax assets, net	42,940,624	10,209,278
Total assets	193,824,234	105,836,130
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'
Accounts payable	5,064,380	10,189,917
Accrued expenses and other current liabilities	4,842,393	4,283,849
Common stock warrants, current	313,425	333,793
Long-term debt, current maturities	1,968,826	954,738
Total current liabilities	12,189,024	15,762,297
Deferred revenue	162,222,189	57,052,020
Common stock warrants, noncurrent	0	657,246
Long-term debt, excluding current maturities	1,989,948	3,955,262
Other liabilities	447,605	166,303
Total liabilities	176,848,766	77,593,128
Stockholders' equity	'	'
Common stock ($.0001 par value, 100,000,000 shares authorized, 53,108,844 and 51,642,520 issued and outstanding at December 31, 2013, and December 31, 2012, respectively	5,310	5,164
Additional paid-in capital	173,498,028	167,588,375
Accumulated deficit	-156,527,870	-139,350,537
Total stockholders' equity	16,975,468	28,243,002
Total liabilities and stockholders' equity	$193,824,234	$105,836,130

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Balance Sheet Parenthetical [Abstract]	'	'
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	53,108,844	51,642,520
Common stock, shares outstanding	53,108,844	51,642,520

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME/LOSS (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues	'	'	'
Research and development	$5,519,300	$8,970,835	$12,725,792
Operating expenses	'	'	'
Selling, general and administrative	13,244,819	11,410,131	23,931,713
Research and development	13,856,500	18,213,036	18,367,348
Patent preparation fees	1,421,218	1,883,405	1,808,168
Restructuring charges	512,944	0	0
Total operating expenses	29,035,481	31,506,572	44,107,229
Operating loss	-23,516,181	-22,535,737	-31,381,437
Decrease (increase) in fair value of common stock warrants	-73,756	804,516	24,436,309
Non-cash interest expense	-1,207,332	-172,993	0
Other income, net	1,497	522	13,061
Loss before income taxes	-24,795,772	-21,903,692	-6,932,067
Benefit from (provision for) income taxes	7,618,439	7,844,153	36,031,646
Net income (loss)	-17,177,333	-14,059,539	29,099,579
Earning (loss) per share: basic	($0.33)	($0.27)	$0.57
Earnings (loss) per share: diluted	($0.33)	($0.27)	$0.09
Weighted average shares: basic	52,368,842	51,639,622	50,929,491
Weighted average shares outstanding: diluted	52,368,842	51,639,622	54,061,650
Comprehensive income (loss)	'	'	'
Net income (loss)	-17,177,333	-14,059,539	29,099,579
Change in net unrealized gain (loss) on short-term investments	0	0	-4,067
Comprehensive income (loss)	($17,177,333)	($14,059,539)	$29,095,512

CONSOLIDATED_STATEMENTS_OF_CHA

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)
Total stockholders' equity at Dec. 31, 2010	'	'	'	'	'
Increase (Decrease) in Stockholders' Equity	'	'	'	'	'
Net income (loss)	$29,099,579	'	'	$29,099,579	'
Change in net unrealized gain (loss) on short-term investments	-4,067	'	'	'	-4,067
Issuance of common stock upon exercise of stock options and warrants (in shares)	'	2,123,454	'	'	'
Issuance of common stock upon exercise of stock options and warrants	-3,946,237	-213	-3,946,024	'	'
Stock-based compensation (in shares)	'	700,000	'	'	'
Stock-based compensation	12,463,772	70	12,463,702	'	'
Tax obligation from stock-based compensation (in shares)	'	-205,545	'	'	'
Tax obligation from stock-based compensation	-1,353,656	-21	-1,353,635	'	'
Fair value of exercised common stock warrants	9,531,911	'	9,531,911	'	'
Excess tax benefit from share-based compensation	0	'	'	'	'
Total stockholders' equity at Dec. 31, 2011	40,770,859	5,164	166,056,693	-125,290,998	0
Total stockholders' equity (in shares) at Dec. 31, 2011	'	51,637,352	'	'	'
Increase (Decrease) in Stockholders' Equity	'	'	'	'	'
Net income (loss)	-14,059,539	'	'	-14,059,539	'
Change in net unrealized gain (loss) on short-term investments	0	'	'	'	'
Issuance of common stock upon exercise of stock options and warrants (in shares)	'	5,168	'	'	'
Issuance of common stock upon exercise of stock options and warrants	-247,833	'	-247,833	'	'
Stock-based compensation	1,779,515	'	1,779,515	'	'
Tax obligation from stock-based compensation	0	'	'	'	'
Excess tax benefit from share-based compensation	0	'	'	'	'
Total stockholders' equity at Dec. 31, 2012	28,243,002	5,164	167,588,375	-139,350,537	0
Total stockholders' equity (in shares) at Dec. 31, 2012	51,642,520	51,642,520	'	'	'
Increase (Decrease) in Stockholders' Equity	'	'	'	'	'
Net income (loss)	-17,177,333	'	'	-17,177,333	'
Change in net unrealized gain (loss) on short-term investments	0	'	'	'	'
Issuance of common stock upon exercise of stock options and warrants (in shares)	506,623	1,508,148	'	'	'
Issuance of common stock upon exercise of stock options and warrants	-2,868,387	-150	-2,868,237	'	'
Stock-based compensation	2,172,597	'	2,172,597	'	'
Tax obligation from stock-based compensation (in shares)	'	-41,824	'	'	'
Tax obligation from stock-based compensation	-178,952	-4	-178,948	'	'
Warrants issued in exchange for services recorded as other assets	272,729	'	272,729	'	'
Fair value of exercised common stock warrants	751,370	'	751,370	'	'
Excess tax benefit from share-based compensation	23,668	'	23,668	'	'
Total stockholders' equity at Dec. 31, 2013	$16,975,468	$5,310	$173,498,028	($156,527,870)	$0
Total stockholders' equity (in shares) at Dec. 31, 2013	53,108,844	53,108,844	'	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:	'	'	'
Net income (loss)	($17,177,333)	($14,059,539)	$29,099,579
Adjustments to reconcile net income (loss) to net cash used in operating activities	'	'	'
Depreciation and other amortization	463,137	419,358	568,288
Increase (decrease) in fair value of warrants	-73,756	804,516	24,436,309
Stock-based compensation	2,263,506	1,779,515	12,463,772
Other noncash income (expense)	48,774	0	0
Changes in assets and liabilities:	'	'	'
Accounts receivable	3,759,484	-2,104,404	365,041
Inventory	-2,873,427	-17,641,922	0
Deferred costs	-19,741,668	-2,591,462	-250,072
Prepaid expenses and other current assets	188,101	-444,251	12,119
Other assets	147,621	-548,419	-4,697
Deferred income taxes, net	-9,599,927	-7,847,802	-36,051,978
Accounts payable, accrued expenses and other current liabilities	-4,566,993	7,550,989	2,659,597
Deferred revenue	105,170,169	16,050,910	41,001,110
Other liabilities	281,302	18,717	147,586
Net cash provided by (used in) operating activities	58,436,502	-20,222,826	25,574,036
Cash flows from investing activities:	'	'	'
Capital expenditures	-857,341	-588,235	-237,023
Collateral for surety bond	0	-1,347,956	0
Proceeds from maturity of short term investments	0	0	40,000,000
Purchases of short term investments	0	0	-25,004,717
Net cash (used in) provided by investing activities	-857,341	-1,936,191	14,758,260
Cash flows from financing activities:	'	'	'
Net proceeds from exercise of warrants and options	2,868,387	9,577	3,946,237
Payment of common stock tendered for employee tax obligations	-178,952	0	-1,353,656
Proceeds from issuance of long-term debt	7,000,000	4,910,000	0
Repayments of long-term debt	-8,000,000	0	0
Excess tax benefit from share-based compensation	23,668	0	0
Net cash provided by financing activities	1,713,103	4,919,577	2,592,581
Net increase (decrease) in cash and cash equivalents	59,292,264	-17,239,440	42,924,877
Cash and cash equivalents at beginning of period	32,017,490	49,256,930	'
Cash and cash equivalents at end of period	91,309,754	32,017,490	49,256,930
Supplemental disclosure of non-cash financing activities:	'	'	'
Reclass of common stock warrant liability to additional paid-in capital upon warrant exercise	$751,370	$0	$9,531,911

Organization_and_Basis_of_Pres

Organization and Basis of Presentation	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure	'
	Organization and Basis of Presentation
	Description of Business
	SIGA Technologies, Inc. (“SIGA” or the “Company”) is a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats. The Company's lead product is Arestvyr ™ (tecovirimat), also known as ST-246®, an orally administered antiviral drug that targets orthopoxviruses. While Arestvyr is not yet licensed as safe or effective by the U.S. Food & Drug Administration, it is a novel small-molecule drug that is being delivered to the Strategic National Stockpile under Project Bioshield.
	Basis of presentation
	The consolidated financial statements are presented in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and reflect the consolidated financial position, results of operations and cash flows for all periods presented.
	The consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies	'
	Summary of Significant Accounting Policies
	Use of Estimates
	The consolidated financial statements and related disclosures are prepared in conformity with accounting principles generally accepted in the United States of America. Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the period reported. The most significant estimates include the variables used in the calculation of fair value of stock-based awards including options and warrants granted or issued by the Company; reported amounts of revenue and expenses; impairment of goodwill; and the realization of deferred tax assets. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the financial statements in the period they are determined to be necessary. Actual results could differ from these estimates.
	Cash Equivalents, Short-term Investments and Marketable Securities
	The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Highly liquid investments with maturities greater than three months and less than one year are classified as short-term investments. Such investments are generally money market funds, bank certificates of deposit, and U.S. Treasury bills.
	The Company classifies short-term investments and marketable securities with readily determinable fair values as “available-for-sale.” Investments in securities that are classified as available-for-sale are measured at fair market value in the balance sheet and unrealized holding gains and losses on investments are reported as a separate component of stockholders’ equity until realized.
	Concentration of Credit Risk
	The Company has cash in bank accounts that exceed the Federal Deposit Insurance Corporation insured limits. The Company has not experienced any losses on its cash accounts and no allowance has been provided for potential credit losses because management believes that any such losses would be minimal, if any.
	Accounts Receivable
	Accounts receivable are recorded net of provisions for doubtful accounts. At December 31, 2013 and 2012, 100% of accounts receivables represented receivables from National Institutes of Health (“NIH”) and Biomedical Advanced Research and Development Authority (“BARDA”). An allowance for doubtful accounts is based on specific analysis of the receivables. At December 31, 2013 and 2012, the Company had no allowance for doubtful accounts.
	Inventory
	Inventories are stated at the lower of cost or estimated realizable value. The Company capitalizes inventory costs associated with the Company’s products when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. Inventory is evaluated for impairment periodically to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value. If certain batches or units of product no longer meet quality specifications or become obsolete due to expiration, the Company records a charge to write down such unmarketable inventory to its estimated realizable value.
	Property, Plant and Equipment
	Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation is provided on a straight-line method over the estimated useful lives of the various asset classes. The estimated useful lives are as follows: 5 years for laboratory equipment; 3 years for computer equipment; and 7 years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the estimated useful lives of the assets or the lease term. Maintenance, repairs and minor replacements are charged to expense as incurred.
	Revenue Recognition
	Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, collectability is reasonably assured, title and risk of loss have been transferred to the customer and there are no further contractual obligations.
	Certain arrangements may provide for multiple deliverables, in which there may be a combination of: up-front licenses; research, development, regulatory or other services; and delivery of product. Multiple deliverable arrangements can be divided into separate units of accounting if the deliverables in the arrangement meet the following criteria: (i) the delivered item(s) have value to the customer on a standalone basis and (ii) in circumstances in which an arrangement includes a general right of return with respect to delivered items, then performance of the remaining deliverables must be considered probable and substantially in control of the Company. If multiple deliverables cannot be divided into separate units of accounting then the deliverables must be combined into a single unit of accounting.
	Total consideration in a multiple deliverable arrangement is allocated to units of accounting on a relative fair value of selling price basis. Consideration allocated to a delivered item or unit of accounting is limited to the amount that is not contingent upon delivery of additional items.
	Direct costs incurred by the Company and associated with the deferral of revenue for a unit of accounting will also be deferred and will be recognized as expenses over the same period that the related deferred revenue is recognized as revenue.
	Subject to the above, payments for development activities are recognized as revenue as earned, over the period of effort. Funding for the acquisition of capital assets under cost-plus-fee contracts or grants is evaluated for appropriate recognition as a reduction to the cost of the asset, a financing arrangement, or revenue based on the specific terms of the related grant or contract.
	For the years ended December 31, 2013, 2012, and 2011, revenues from NIH and BARDA were 100%, 100% and 96%, respectively, of total revenues recognized by the Company.
	Research and Development
	Research and development expenses include costs directly attributable to the conduct of research and development programs, including employee related costs, materials, supplies, depreciation on and maintenance of research equipment, the cost of services provided by outside contractors, including services related to the Company’s clinical trials and facility costs, such as rent, utilities, and general support services. All costs associated with research and development are expensed as incurred. Costs related to the acquisition of technology rights, for which development work is still in process, and that have no alternative future uses, are expensed as incurred.
	Goodwill
	The Company evaluates goodwill for impairment at least annually or as circumstances warrant. The impairment review process compares the fair value of the reporting unit in which goodwill resides to its carrying value. The Company operates as one business and one reporting unit. Therefore, the goodwill impairment analysis is performed on the basis of the Company as a whole, using the market capitalization of the Company as an estimate of its fair value.
	Share-based Compensation
	Stock-based compensation expense for all share-based payment awards made to employees and directors is determined on the grant date; for options awards, fair value is estimated using the Black-Scholes model and for stock appreciation rights (“SARs”), fair value is estimated using a Monte Carlo method. The value of the portion of the award that is ultimately expected to vest is recorded as expense over the requisite service periods in the Company’s consolidated statement of operations.
	These compensation costs are recognized net of an estimated forfeiture rate over the requisite service periods of the awards. Forfeitures are estimated on the date of the respective grant and revised if actual or expected forfeiture activity differs from original estimates.
	Income Taxes
	The Company recognizes income taxes utilizing the asset and liability method of accounting for income taxes. Under this method, deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities at enacted tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is established if it is more likely than not that some or the entire deferred tax asset will not be realized. The recognition of a valuation allowance for deferred taxes requires management to make estimates and judgments about the Company’s future profitability which are inherently uncertain.
	Net Loss per Share
	The objective of basic earning per share (“EPS”) is to measure the performance of an entity over the reporting period by dividing income (loss) by the weighted average shares outstanding. The objective of diluted EPS is consistent with that of basic EPS, except that it also gives effect to all potentially dilutive common shares outstanding during the period.
	The following is a reconciliation of the basic and diluted net income (loss) per share computation:
		Year Ended December 31,
		2013				2012			2011
	Net (loss) income for basic EPS	$	(17,177,333	)		$	(14,059,539	)	$	29,099,579
	Change in fair value of warrants	—				—			24,436,309
	Net loss (income) for diluted EPS	$	(17,177,333	)		$	(14,059,539	)	$	4,663,270
	Weighted-average shares: basic	52,368,842				51,639,622			50,929,491
	Effect of potential common shares	—				—			3,132,159
	Weighted-average shares: diluted	52,368,842				51,639,622			54,061,650
	Earnings (loss) per share: basic	$	(0.33	)		$	(0.27	)	$	0.57
	Earnings (loss) per share: diluted	$	(0.33	)		$	(0.27	)	$	0.09
	Anti-dilutive employee share-based awards, excluded	—				—			504,668
	The diluted earnings per share calculation reflects the effect of the assumed exercise of outstanding warrants and any corresponding elimination of the benefit included in operating results from the change in fair value of the warrants. Diluted shares outstanding include the dilutive effect of in-the-money options and warrants, unvested restricted stock and restricted stock units. The dilutive effect of such equity awards is calculated based on the average share price for each fiscal period using the treasury stock method. Under the treasury stock method, the amount the employee must pay for exercising stock options, the average amount of compensation cost for future service that the Company has not yet recognized, and the amount of tax benefits that would be recorded in additional paid-in capital when the award becomes deductible, are collectively assumed to be used to repurchase shares.
	The Company incurred losses for the years ended December 31, 2013 and 2012 whereas for the year ended December 31, 2011, the Company had net income. For all periods presented, certain equity instruments are excluded from the calculation of diluted earnings (loss) per share as the effect of such shares is anti-dilutive. The weighted average number of equity instruments excluded consist of:
		Year Ended December 31,
		2013			2012			2011
	Stock Options	2,725,632			2,865,861			504,668
	Stock-Settled Stock Appreciation Rights	439,056			421,020			—
	Restricted Stock Units	981,645			351,011			—
	Warrants	1,802,820			2,263,538			—
	As discussed in Note 5, the appreciation of each SSAR was capped at a determined maximum value. As a result, the weighted average number shown in the table above for stock-settled stock appreciation rights reflects the weighted average maximum number of shares that could be issued.
	Fair Value of Financial Instruments
	The carrying value of cash and cash equivalents, accounts payable and accrued expenses approximates fair value due to the relatively short maturity of these instruments. Common stock warrants which are classified as liabilities are recorded at their fair market value as of each reporting period.
	The measurement of fair value requires the use of techniques based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. The inputs create the following fair value hierarchy:
	•	Level 1 – Quoted prices for identical instruments in active markets.
	•	Level 2 – Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.
	•	Level 3 – Instruments where significant value drivers are unobservable to third parties.
	The Company uses model-derived valuations where inputs are observable in active markets to determine the fair value of certain common stock warrants on a recurring basis and classify such warrants in Level 2. The Company utilizes the Black-Scholes model consisting of the following variables: (i) the closing price of SIGA’s common stock; (ii) the expected remaining life of the warrant; (iii) the expected volatility using a weighted-average of historical volatilities from a combination of SIGA and comparable companies; and (iv) the risk-free market rate. At December 31, 2013 and 2012, the fair value of such warrants was as follows:
			2013				2012
	Common stock warrants, current		$	313,425			$	333,793
	Common stock warrants, non-current		—				657,246
		$	313,425			$	991,039
As of December 31, 2013 and 2012, the Company had $4.0 million and $5.0 million outstanding, respectively, from a loan entered into on December 31, 2012 (refer to Note 6 for details). The fair value of the loan, which is measured using Level 2 inputs, approximates book value at December 31, 2013 and 2012.
For the years ended December 31, 2013 and 2012, SIGA did not hold any Level 3 securities.
Legal Contingencies
The Company is subject to certain contingencies arising in the ordinary course of business. The Company records accruals for these contingencies to the extent that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, that amount is accrued. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, the lowest amount in the range is accrued. We record anticipated recoveries under existing insurance contracts when recovery is assured.
Segment Information
The Company is managed and operated as one business. The entire business is managed by a single management team that reports to the chief executive officer. The Company does not operate separate lines of business or separate business entities with respect to any of its product candidates. Accordingly, the Company does not prepare discrete financial information with respect to separate product areas or by location and only has one reportable segment.
Recent Accounting Pronouncements
In February 2013, the Financial Accounting Standards Board (“FASB”) issued new guidance on the reporting of reclassifications from accumulated other comprehensive income to net income. The new guidance does not change the requirements for reporting net income or other comprehensive income in financial statements but requires disclosures regarding the reclassification of accumulated other comprehensive income by component into net income. The Company’s adoption of this guidance on January 2, 2013 did not have a material effect on our financial statements.
In July 2013, the FASB issued new guidance on the financial statement presentation of unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The new guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company does not anticipate a material impact to the Company’s financial position, results of operations or cash flows as a result of this change.

Procurement_Contract_and_Resea

Procurement Contract and Research Agreements	12 Months Ended
	Dec. 31, 2013
Research and Development [Abstract]	'
Procurement Contract and Research Agreements	'
	Procurement Contract and Research Agreements
	Procurement Contract
	On May 13, 2011, the Company signed a contract with BARDA (the “BARDA Contract”) pursuant to which SIGA agreed to deliver two million courses of Arestvyr to the Strategic Stockpile. The base contract, worth approximately $463 million, includes $54 million related to development and supportive activities and contains various options to be exercised at BARDA’s discretion. The period of performance for development and supportive activities runs until 2020. As originally issued, the BARDA Contract included an option for the purchase of up to 12 million additional courses of Arestvyr; however, following a protest by a competitor of the Company, BARDA issued a contract modification on June 24, 2011 pursuant to which it deleted the option to purchase the additional courses. Under the BARDA Contract as modified, BARDA has agreed to buy from SIGA 1.7 million courses of Arestvyr. Additionally, SIGA will contribute to BARDA 300,000 courses manufactured primarily using federal funds provided by the U.S. Department of Health and Human Services (“HHS”) under prior development contracts. The BARDA Contract as modified also contains options that will permit SIGA to continue its work on pediatric and geriatric versions of the drug as well as use Arestvyr for smallpox prophylaxis. As described in Note 14, the amount of profits SIGA will retain pursuant to the BARDA Contract may be adversely affected by the outcome of PharmAthene’s action against SIGA.
	In the fourth quarter of 2011, SIGA received approximately $41.0 million in advance payments under the BARDA Contract. In the fourth quarter of 2012, SIGA received FDA concurrence with respect to its product labeling strategy in accordance with the BARDA Contract and received the related milestone payment of approximately $12.3 million. In May 2013, after BARDA notified SIGA that the Company had successfully completed the milestone requirements for the Final Drug Product Commercial Validation batches, the Company received a milestone payment of approximately $8.2 million. In 2013, in addition to the $8.2 million milestone payment, the Company received approximately $101.5 million from BARDA, of which approximately $96.1 million was for the delivery of 725,000 courses of Arestvyr and approximately $5.4 million was for reimbursement related to research and development services and supportive activities.
	The BARDA Contract is a multiple deliverable arrangement comprising delivery of courses and covered research and development activities. The BARDA Contract provides certain product replacement rights with respect to delivered courses. For this reason, recognition of revenue that might otherwise occur upon delivery of courses is expected to be deferred until the Company’s obligations related to potential replacement of delivered courses are satisfied. The Company assessed the selling price for each of the aforementioned deliverables - research and development activities and drug product. The selling price of certain reimbursed research and development services was determined by reference to existing and past research and development grants and contracts between the Company and various government agencies. The selling price of drug product was determined by reference to other Companies’ sales of drug products such as antiviral therapeutics, orphan drugs and drugs with potential life-saving impact similar to Arestvyr, including products delivered to the Strategic Stockpile.
	The Company has recognized revenue for reimbursement of certain BARDA Contract research and development services. Cash inflows related to delivery of courses will continue to be recorded as deferred revenue. In addition, direct costs incurred by the Company to fulfill the delivery of courses under the BARDA Contract are being deferred and will be recognized as expenses over the same period that the related deferred revenue is recognized as revenue.
	As of December 31, 2013 and 2012, deferred direct costs under the BARDA Contract of approximately $22.6 million and $2.8 million, respectively, are included in deferred costs on the consolidated balance sheets. As of December 31, 2013, the Company recorded $162.2 million of deferred revenue for the delivery of approximately 725,000 courses of Arestvyr to the Strategic Stockpile and certain research and development services provided as part of the BARDA Contract. For the year ended December 31, 2013, revenue from reimbursed research and development was $1.2 million. In addition to the 725,000 courses of Arestvyr that were accepted by the Strategic Stockpile and resulted in payment, the Company also delivered 195,000 courses at no cost to BARDA in accordance with the BARDA Contract, of which 62,000 were accepted in 2013 and 133,000 were accepted in 2014,
	In February 2014, the Company delivered approximately 256,000 courses of Arestvyr accepted into the Strategic Stockpile, of which approximately 192,000 courses will be invoiced for $25.4 million and the remainder will be at no cost to BARDA.
	Research Agreements
	The Company obtains funding from the contracts and grants it obtains from various agencies of the U.S. Government to support its research and development activities. Currently, the Company has one contract and two grants with varying expiration dates through July 2016 that provide for potential future aggregate research and development funding for specific projects of approximately $13.9 million. This amount includes, among other things, options that may or may not be exercised at the U.S. government’s discretion. Moreover, the contract and grants contain customary terms and conditions including the U.S. Government’s right to terminate or restructure a grant for convenience at any time.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Stockholders' Equity	'
	Stockholders’ Equity
	On December 31, 2013, the Company’s authorized share capital consisted of 110,000,000 shares, of which 100,000,000 are designated common shares and 10,000,000 are designated preferred shares. The Company’s Board of Directors is authorized to issue preferred shares in series with rights, privileges and qualifications of each series determined by the Board.
	At December 31, 2013 and 2012, the fair market value of outstanding liability classified warrants was $313,425 and $991,039, respectively. The Company applied the Black-Scholes model to calculate the fair values of the respective derivative instruments using the contractual term of the warrants. Management estimates the expected volatility using a combination of the Company’s historical volatility and the volatility of a group of comparable companies.
	For the years ended December 31, 2013 and 2012, the Company recorded a loss of $73,756 and a gain of $804,516 related to net changes in fair value for liability classified warrants outstanding during the respective periods.
	On April 30, 2013, SIGA entered into a Services Agreement with MacAndrews & Forbes LLC (“M&F”) for certain professional and administrative services. The Services Agreement has a term of three years. As consideration for the Services Agreement, SIGA issued warrants to M&F to acquire 250,000 shares of common stock at an exercise price of $3.29 per share. The warrants are fully vested, immediately exercisable and remain exercisable for two years from issuance. The grant-date fair value, determined using the Black-Scholes model as previously described, is recorded as an asset with a corresponding increase to equity. The asset is amortized over the contractual term of the warrant.
	2008 Financing
	On June 19, 2008, SIGA entered into a letter agreement (as amended, the “Letter Agreement”) that expired on June 19, 2010, with MacAndrews & Forbes LLC (“M&F”), a related party, for M&F’s commitment to invest, at SIGA’s discretion or at M&F’s option, up to $8 million in exchange for (i) SIGA common stock and (ii) warrants to purchase 40% of the number of SIGA shares acquired by M&F. In consideration for the commitment of M&F reflected in the Letter Agreement, on June 19, 2008, M&F received warrants to purchase 238,000 shares of SIGA common stock, initially exercisable at $3.06 (the “Commitment Warrants”). The Commitment Warrants were exercisable until June 19, 2012. On June 19, 2012, the Commitment Warrants were amended to extend expiration to June 19, 2014. Due to certain anti-dilution provisions, the Commitment Warrants are recorded as a liability, and consequently the “mark-to-market” adjustment to the fair value from the extended term was accounted immediately upon modification.
	In 2009, SIGA issued to M&F 816,993 shares of common stock and 326,797 warrants (the “2009 Warrants”) to acquire common stock in exchange for total proceeds of $2.5 million. The warrants were exercisable for a term of four years from issuance for an exercise price of $3.519 per share. The 2009 Warrants were not exercised and as a result expired during the year ended December 31, 2013.
	On June 18, 2010, M&F notified SIGA of its intention to exercise its right to invest $5.5 million, the remaining amount available under the Letter Agreement following earlier investments and entered into a Deferred Closing and Registration Rights Agreement dated as of June 18, 2010 with the Company. On July 26, 2010, upon satisfaction of certain customary closing conditions, including the expiration of the applicable waiting period pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, M&F funded the $5.5 million purchase price to SIGA in exchange for the issuance of (i) 1,797,386 shares of common stock and (ii) warrants to purchase 718,954 shares of SIGA common stock at an exercise price of $3.519 per share; the warrants are exercisable for a term of four years from issuance.
	The number of shares issuable pursuant to the warrants granted under the Letter Agreement, as well as the exercise price of those warrants, may be subject to adjustment as a result of the effect of future equity issuances on certain anti-dilution provisions in the related warrant agreements.
	2006 Placements
	In 2006, the Company issued 1,000,000 warrants with an initial exercise price of $4.99 per share (the “2006 Warrants”). As of December 31, 2013, there are no remaining 2006 Warrants as all issuances were either exercised or expired during the fourth quarter of 2013.
	The Company accounted for the warrants in accordance with the authoritative guidance which requires that free-standing derivative financial instruments that require net cash settlement be classified as assets or liabilities at the time of the transaction, and recorded at their fair value. Any changes in the fair value of the derivative instruments are reported in earnings or loss as long as the derivative contracts are classified as assets or liabilities.

Stock_Compensation_Plans

Stock Compensation Plans	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock Compensation Plans	'
	Stock Compensation Plans
	The Company’s 2010 Stock Incentive Plan (the “2010 Plan”) was initially adopted in May 2010. The 2010 Plan provided for the issuance of stock options, restricted stock and unrestricted stock with respect to an aggregate of 2,000,000 shares of the Company’s Common Stock to employees, consultants and outside directors of the Company. On May 17, 2011, the 2010 Plan was amended to provide for the issuance of restricted stock units (“RSUs”) and on February 2, 2012, the 2010 Plan was amended to provide for the issuance of SARs. Effective April 25, 2012, the 2010 Plan was amended to increase the maximum number of shares of Common Stock available for issuance to an aggregate of 4,500,000 shares. The vesting period for awards granted under the 2010 Plan, except those granted to outside directors, is determined by the Compensation Committee of the Board of Directors. The Compensation Committee also determines the expiration date of each equity award, however, stock options and SARs may not be exercisable more than ten years after the date of grant. as the maximum term of equity awards issued under the 2010 Plan is ten years.
	For the years ended December 31, 2013, 2012 and 2011, the Company recorded stock-based compensation expense, including stock options, SARs, RSUs and certain warrant amortization, of approximately $2.3 million, $1.8 million and $12.5 million, respectively.
	Stock Options
	Stock option awards provide holders the right to purchase shares of Common Stock at prices determined by the Compensation Committee and must have an exercise price equal to or in excess of the fair market value of the Company’s common stock at the date of grant.
	The fair value of option grants were estimated at the date of grant during the years ended December 31, 2013, 2012, and 2011 based upon the following range of assumptions:
		2013			2012		2011
	Expected volatility	67	%		77	%	76	%
	Expected dividend yield	—	%		—	%	—	%
	Risk-free interest rate	0.84% - 1.29%			0.98% - 1.24%		1.94	%
	Expected life	6 years			6 years		6 years
	Expected volatility has been estimated using a combination of the Company’s historical volatility and the historical volatility of a group of comparable companies, both using historical periods equivalent to the options’ expected lives. The expected dividend yield assumption is based on the Company’s intent not to issue a dividend in the foreseeable future. The risk-free interest rate assumption is based upon observed interest rates for securities with maturities approximating the options’ expected lives. The expected life was estimated based on historical experience and expectation of employee exercise behavior in the future giving consideration to the contractual terms of the award.
	A summary of the Company’s stock option activity is as follows:
		Number of			Weighted			Weighted	Aggregate
		Options			Average Exercise			Average	Intrinsic Value
					Price			Remaining Life	(in thousands)
								(in years)
	Outstanding at January 1, 2013	2,902,708			$	4.28
	Granted	27,000			3.87
	Exercised	(506,623	)		1.37
	Canceled/Expired	(69,455	)		4.06
	Outstanding at December 31, 2013	2,353,630			$	4.91		5.09	$	849,950
	Vested and expected to vest at December 31, 2013	2,343,414			$	4.91		5.1	$	844,331
	Exercisable at December 31, 2013	2,013,960			$	5.09		4.99	$	663,128
	As of December 31, 2013, $189,000 of total remaining unrecognized stock-based compensation cost related to stock options is expected to be recognized over the weighted-average remaining requisite service period of 1.06 years. The total fair value of vested stock options was $0.6 million, $0.9 million and $2.2 million for the years ended December 31, 2013, 2012 and 2011, respectively.
	The total intrinsic value of stock options exercised was $959,000, $5,000 and $12.3 million for the years ended December 31, 2013, 2012 and 2011, respectively. The intrinsic value represents the amount by which the market price of the underlying stock exceeds the exercise price of an option.
	The weighted average fair value at the date of grant for stock options granted during the years ended December 31, 2013, 2012 and 2011 was $2.34, $1.77 and $7.01.
	As of December 31, 2013 and 2012, 500,000 of the Company’s outstanding options, respectively, were subject to specific performance conditions consisting of minimum cash receipts thresholds and regulatory approval of our lead drug candidate. During the year ended December 31, 2013, the performance conditions relating to minimum cash receipts were achieved making 300,000 of the aforementioned options exercisable. The remaining 200,000 options with performance conditions relating to regulatory approval have not been achieved, thus these options are not exercisable at December 31, 2013.
	Stock Appreciation Rights
	Stock-settled stock appreciation rights (“SSARs”) provide holders the right to purchase shares of Common Stock at prices determined by the Compensation Committee and must have an exercise price equal to or in excess of the fair market value of the Company’s common stock at the date of grant. Upon exercise, the gain, or intrinsic value, is settled by the delivery of SIGA stock to the employee.
	During the year ended December 31, 2012, the Company granted 1.4 million shares of SSARs at a weighted average grant-date fair value of $0.68 per share. The exercise price of a SSAR is equal to the closing market price on the date of grant. The granted SSARs vest in equal annual installments over a period of three years and expire no later than seven years from the date of grant. Moreover, the appreciation of each SSAR was capped at a determined maximum value. At December 31, 2013 and 2012, due to the cap on value the maximum number of shares that could be issued in the future was 407,705 and 453,465, respectively.
	The fair value of granted SSARs has been estimated utilizing a Monte Carlo method. The Monte Carlo method is a statistical simulation technique used to provide the grant-date fair value of an award. As the issued SSARs were capped at maximum values, such attribute was considered in the simulation. The following table presents the weighted-average assumptions utilized in the valuations:
			2012
	Expected volatility		71	%
	Expected life from grant date		4.5 years
	Expected dividend yield		—	%
	Risk-free interest rate		0.61	%
	The Company calculates the expected volatility using a combination of SIGA’s historical volatility and the volatility of a group of comparable companies. The expected life from grant date was estimated based on the expectation of exercise behavior in consideration of the maximum value and contractual term of the SSARs. The dividend yield assumption is based on the Company’s intent not to issue a dividend in the foreseeable future. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected life of the SSARs.
	A summary of the Company’s SSAR activity is as follows:
		Number of			Weighted			Weighted	Aggregate
		SSARs			Average Exercise			Average	Intrinsic Value
					Price			Remaining Life	(in thousands)
								(in years)
	Outstanding at January 1, 2013	1,420,951			$	3.53
	Granted	—			—
	Exercised	(8,750	)		3.53
	Canceled/Expired	(101,301	)		3.53
	Outstanding at December 31, 2013	1,310,900			$	3.53		5.09	$	—
	Vested and expected to vest at December 31, 2013	1,285,297			$	3.53		5.09	$	—
	Exercisable at December 31, 2013	459,684			$	3.53		5.09	$	—
	As of December 31, 2013, $302,000 of total remaining unrecognized stock-based compensation cost related to SSARs is expected to be recognized over the weighted-average remaining requisite service period of 1.09 years. The total fair value of vested SSARs was $317,000, $0 and $0 for the years ended December 31, 2013, 2012 and 2011, respectively. The total intrinsic value of SSARs exercised was $4,000,$0 and $0 for the years ended December 31, 2013, 2012 and 2011, respectively. The intrinsic value represents the amount by which the market price of the underlying stock exceeds the exercise price of a SSAR.
	Restricted Stock Awards/Restricted Stock Units
	RSUs awarded to employees vest in equal annual installments over a three-year period and RSUs awarded to directors of the Company vest over a one-year period. A summary of the Company’s RSU activity is as follows:
		Number of			Weighted
		RSUs			Average Grant-Date Fair Value
	Outstanding at January 1, 2013	460,000			$	2.82
	Granted	775,000			2.98
	Vested	(253,332	)		2.69
	Canceled/Expired	(15,000	)		2.82
	Outstanding at December 31, 2013	966,668			$	2.98
	As of December 31, 2013, $1.7 million of total remaining unrecognized stock-based compensation cost related to RSUs is expected to be recognized over the weighted-average remaining requisite service period of 1.67 years. The weighted average fair value at the date of grant for restricted stock awards granted during the years ended December 31, 2013, 2012 and 2011 was $2.98, $2.82 and $14.26 per share, respectively. The total fair value of restricted stock and restricted stock units vested during the years ended December 31, 2013, 2012 and 2011 was $0.7 million, $0 and $10.0 million.
	Warrants
	A summary of the Company’s warrant activity is as follows:
	Number of			Weighted Average
	Warrants			Exercise Price
Outstanding at January 1, 2013	2,253,902			$	3.3
Granted	250,000			3.29
Exercised	(815,568	)		2.92
Canceled/Expired	(472,108	)		3.81
Outstanding at December 31, 2013	1,216,226			$	3.36
Warrants represent the right to purchase shares of Common Stock at contractual exercise prices. As of December 31, 2013, all outstanding warrants are exercisable.

Debt

Debt	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Debt	'
	Debt
	In December 2012, the Company entered into a loan agreement (“Loan Agreement”) with General Electric Capital Corporation (“GE Capital”) to provide the Company a term loan of $5.0 million with a fixed interest rate of 9.85% per annum and a revolving line of credit of $7.0 million with a variable interest rate. Borrowings under the revolving line of credit are based on eligible outstanding accounts receivable and will bear interest at a rate per annum equal to 5.25% plus the higher of: (a) 1.50%, and (b) three-month LIBOR divided by a defined factor. The term of the loan is three years.
	As of December 31, 2013 and 2012,$4.0 million and $5.0 million, respectively, was outstanding. Under the Loan Agreement, the Company may draw down from the revolving line of credit up to 85% of qualified eligible accounts receivable as described in the Loan Agreement. As of December 31, 2013 and 2012, no amounts were available to borrow against the revolving line of credit as there were no eligible accounts receivable.
	Under the Loan Agreement, the Company was required to make interest-only monthly payments from February 2013 through June 2013. Monthly payments of $167,000 in principal plus accrued interest commenced on July 1, 2013.
	The loan is collateralized by substantially all of the Company’s assets other than Arestvyr or any intellectual property related to Arestvyr. The Loan Agreement contains affirmative and negative covenants including certain customary financial covenants. The Company was in compliance with all financial debt covenants as of December 31, 2013 and 2012.
	In connection with securing the Loan Agreement, the Company incurred approximately $386,000 of debt issue costs which are recorded as deferred costs and allocated between other current assets and other assets. Furthermore, the Company incurred $90,000 of costs which were accounted for as a debt discount and thus, are recorded as a direct reduction of the face amount of the debt. The debt issue costs and debt discount will be amortized to interest expense over the term of the Loan Agreement.
	The aggregate amount of required principal payments at December 31, 2013 are as follows:
	2014	$	2,000,000
	2015	2,000,000
	Unamortized discount	(41,226		)
	Total	$	3,958,774

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	Related Party Transactions
	On December 1, 2009, the Company entered into an Office Services Agreement with an affiliate of M&F to occupy office space for approximately $8,000 per month. An amendment in February 2012 increased the monthly payment to $12,000 to appropriately reflect expanded use of space. The Office Services Agreement was canceled effective March 31, 2013.
	In October 2012, the Company funded a letter of credit and deposit to take advantage of a lease for office space secured by an affiliate of M&F from a third party landlord on behalf of the Company. Pursuant to such letter of credit, in January 2013 the Company entered into a sublease in which the Company will pay all costs associated with the lease, including rent. All payments made by the Company pursuant to the sublease will either be directly or indirectly made to the third-party landlord and not retained by M&F or any affiliate. The new sublease replaced the current Office Services Agreement that is described in the previous paragraph, and occupancy commenced on April 1, 2013. The sublease allows for a free rent period of five months beginning April 1, 2013; subsequent to the free rent period, monthly rent payments are $60,000 for the first five years and $63,000 for the next two years. Upon expiration on September 1, 2020, the sublease and lease provides for two consecutive five year renewal options.
	A member of the Company’s Board of Directors is a member of the Company’s outside counsel. During the years ended December 31, 2013, 2012 and 2011, the Company incurred costs of $1.8 million, $2.0 million and $3.1 million, respectively, related to services provided by the outside counsel. On December 31, 2013, the Company’s outstanding payables included $200,000 payable to the outside counsel.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventory	'
	Inventory
	During the year ended December 31, 2013, the Company delivered approximately 787,000 courses accepted into the Strategic Stockpile; due to the deferral of revenue under the BARDA Contract (refer to Note 2), amounts that would be otherwise recorded as cost of goods sold for delivered courses are recorded as deferred costs in the balance sheet. The value of inventory represents the costs incurred to manufacture Arestvyr under the BARDA Contract. Certain of the existing units of Arestvyr were initially manufactured prior to the point at which future commercialization was probable; thus, such cost was expensed as research and development in those respective periods. Additional costs incurred to complete production of courses of Arestvyr will be recorded as inventory and reclassified to deferred costs upon delivery to the extent related revenue is deferred.
	Inventory consisted of the following at December 31, 2013 and 2012:
		2013		2012
	Work in-process	$	6,152,198	$	17,641,922
	Finished goods	14,363,151		—
	Inventory	$	20,515,349	$	17,641,922
	For the year ended December 31, 2012, research and development expense included inventory write-downs of $0.5 million.

Property_Plant_and_Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment	'
	Property, Plant and Equipment
	Property, plant and equipment consisted of the following at December 31, 2013 and 2012:
		2013			2012
	Laboratory equipment	$	2,473,428		$	2,305,410
	Leasehold improvements	3,166,622			2,817,123
	Computer equipment	655,364			458,421
	Furniture and fixtures	488,168			345,287
		6,783,582			5,926,241
	Less - accumulated depreciation	(5,401,509		)	(4,938,372		)
	Property, plant and equipment, net	$	1,382,073		$	987,869
	Depreciation and amortization expense on property, plant, and equipment was $463,137, $419,358, and $568,288 for the years ended December 31,2013, 2012, and 2011, respectively. For the year ended December 31, 2011, in addition to depreciation and amortization expense, the Company incurred non-cash charges of $25,000 in connection with disposals of fixed assets.

Accrued_Expenses_and_Other_Cur

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Accrued Expenses and Other Current Liabilities	'
	Accrued Expenses
	Accrued expenses and other current liabilities consisted of the following at December 31, 2013 and 2012:
		2013		2012
	Loss contingency	$	2,635,270	$	2,491,981
	Bonus	—		250,000
	Professional fees	794,275		579,609
	Vacation	252,410		328,463
	Other	1,160,438		633,796
	Accrued expenses and other current liabilities	$	4,842,393	$	4,283,849

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax	'
	Income Taxes
	At December 31, 2013 and 2012, the Company's provision (benefit) for income taxes is comprised of the following:
		2013				2012				2011
	Current:
	Federal	$	1,608,033			$	—			$	—
	State and local	373,455				3,649				20,332
	Total current provision (benefit)	1,981,488				3,649				20,332
	Deferred:
	Federal	(10,072,499		)		(7,557,163		)		(35,493,317		)
	State and local	472,572				(290,639		)		(558,661		)
	Total deferred provision (benefit)	(9,599,927		)		(7,847,802		)		(36,051,978		)
	Total provision (benefit)	$	(7,618,439	)		$	(7,844,153	)		$	(36,031,646	)
	At December 31, 2013 and 2012, the Company’s deferred tax assets and liabilities are comprised of the following:
		2013				2012
	Deferred income tax assets:
	Net operating losses	$	7,750,690			$	36,764,901
	Deferred research and development costs	2,278,397				2,950,555
	Amortization of intangible assets	1,342,555				1,572,281
	Share-based compensation	2,166,125				1,768,990
	Depreciation	604,973				709,184
	Deferred revenue	48,685,086				4,403,266
	Alternative minimum tax credits	1,608,033				—
	Loss contingency	942,529				892,129
	Other	554,777				212,483
	Deferred income tax assets	65,933,165				49,273,789
	Less: valuation allowance	(4,442,929		)		(4,328,233		)
	Deferred income tax assets, net of valuation allowance	$	61,490,236			$	44,945,556
	Deferred income tax liabilities:
	Amortization of goodwill	(224,908		)		(203,682		)
	Capitalized contract costs	(7,940,796		)		(1,017,269		)
	Deferred income tax assets, net	$	53,324,532			$	43,724,605
	As of December 31, 2013, $23.5 million federal net operating loss carryforwards which expire in 2021 to 2032 was available to offset taxable income. As a result of a cumulative change in stock ownership occurring in a prior year, approximately $3.1 million of the federal net operating loss carryforwards are subject to annual limitation under IRC Section 382. In addition, the utilization of approximately $1.6 million of federal net operating losses attributable to excess tax deductions on share-based compensation activity will be realized as a benefit to Additional Paid-in Capital when such deductions are applied to income taxes payable. In 2012, previously available NOLs of approximately $1.2 million expired.
	For the year ended December 31, 2012, the Company incurred net losses for tax purposes and consequently, recognized an income tax benefit of $7.8 million. For the year ended December 31, 2011, the benefit from income taxes of $36.0 million mainly reflects net losses as well as a partial reduction of its valuation allowance as a significant portion of the Company’s deferred tax assets became realizable on a “more likely than not” basis primarily as a result of the execution of the BARDA Contract and forecasts of pre-tax earnings. Prior to June 30, 2011, the Company provided a tax valuation allowance on our United States federal and state deferred tax assets based on the Company’s evaluation that such assets were not “more likely than not” to be realized.
	As of December 31, 2013, a valuation allowance of approximately $4.4 million relates to certain deferred tax assets that the Company does not expect to realize on a more likely than not basis. The recognition of a valuation allowance for deferred taxes requires management to make estimates and judgments about the Company’s future profitability which are inherently uncertain. This includes assessing available positive and negative evidence to determine if sufficient future tax income will be generated to utilize existing deferred tax assets. If the current estimates of future taxable income are reduced or not realized, for example, based on the outcome in PharmAthene's action against the Company described in Note 13, the Company’s assessment regarding the realization of deferred tax assets could change. Future changes in the estimated amount of deferred taxes expected to be realized will be reflected in the Company’s financial statements in the period the estimate is changed with a corresponding adjustment to operating results. Changes in estimates may occur often and can have a significant favorable or unfavorable impact on the Company’s operating results from period to period.
	The Company’s effective tax rate differs from the U.S. Federal Statutory income tax rate of 35% as follows:
		2013			2012			2011
	Statutory federal income tax rate	(35.0	)%		(35.0	)%		(35.0	)%
	State tax benefit	2.9	%		(1.4	)%		0.3	%
	Gain (loss) from fair value of common warrants	0.1	%		(1.3	)%		(123.4	)%
	Share-based compensation	0.4	%		0.8	%		24.8	%
	Other	0.3	%		0.5	%		1.4	%
	Valuation allowance on deferred tax assets	0.6	%		0.5	%		(387.6	)%
	Effective tax rate	(30.7	)%		(35.9	)%		(519.5	)%
	For the years ended December 31, 2013 and 2012, the Company's effective tax rate differs from the statutory rate principally due to state and local taxes and other permanent differences.  For the year ended December 31, 2011, the Company's effective tax rate differs from the federal statutory rate due to the partial reversal of its valuation allowance as certain deferred tax assets became realizable on a more-likely-than basis as well as the decrease in the fair value of common stock warrants which is not deductible for tax purposes.
	The Company applies the applicable authoritative guidance which prescribes a comprehensive model for the manner in which a company should recognize, measure, present and disclose in its financial statements all material uncertain tax positions that the Company has taken or expects to take on a tax return. The Company has no tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within twelve months from December 31, 2013. The Company files federal income tax returns and income tax returns in various state and local tax jurisdictions. The open tax years for U.S. federal, state and local tax returns is generally 2010 - 2013; open tax years relating to unused net operating loss carryforwards (“NOLs”) begin in 1998. In the event that the Company concludes that it is subject to interest and/or penalties arising from uncertain tax positions, the Company will present interest and penalties as a component of income taxes. No amounts of interest or penalties were recognized in the Company’s consolidated financial statements for each of the years in the three-year period ended December 31, 2013.

Restructuring_Charges

Restructuring Charges	12 Months Ended
	Dec. 31, 2013
Restructuring Charges [Abstract]	'
Restructuring and related activities disclosure	'
	Restructuring
	In the fourth quarter of 2013, the Company began an optimization program to increase efficiencies within its operations (the “Optimization Program”). This program, which included a reduction in employee headcount, is intended to align the Company's resources, staff and efforts with the most promising growth opportunities. With the implementation of the Optimization Program, the Company is targeting a $6 million reduction in annual operating expenses, of which a substantial portion of the reduction has been implemented at December 31, 2013. For the year ended December 31, 2013, the Company recorded a restructuring charge of 512,944 which included a non-cash asset impairment for the write-off of certain prepaid assets. The following table summarizes the activity for the restructuring:
		Accrued as of January 1, 2013		Charges		Payments			Non-Cash Items			Accrued as of December 31, 2013
	Severance Charges	$	—	$	324,615	$	(206,385	)	$	—		$	118,230
	Asset Impairments	—		188,329		—			(188,329		)	—
		$	—	$	512,944	$	(206,385	)	$	(188,329	)	$	118,230

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	Operating lease commitments
	The Company leases its Corvallis, Oregon, facilities and office space under an operating lease, most recently amended in November 2012, which expires in 2017 and includes a renewal option for an extension of five years. In January 2013, we entered into a sublease with an affiliate of M&F for corporate office space under an operating lease which commenced in April 2013 and expires in 2020 (refer to Note 9 for further description of the lease arrangement). The respective leases contain annual escalation clauses, renewal provisions and generally require us to pay utilities, insurance, taxes and other operating expenses. Rental expense, including charges for maintenance, utilities, real estate taxes and other operating expenses, totaled $1.4 million, $1.0 million and $827,000 for the years ended December 31, 2013, 2012 and 2011, respectively.
	Future minimum rental commitments under non-cancelable operating leases as of December 31, 2013 are expected to be as follows:
	2014	$	1,602,840
	2015	1,622,508
	2016	1,642,176
	2017	1,661,844
	2018	734,360
	Thereafter	1,268,440
	Total	$	8,532,168
	Other
	In December 2006, PharmAthene, Inc. (“PharmAthene”) filed an action against SIGA in the Delaware Court of Chancery (the “Court” or “Court of Chancery”) captioned PharmAthene, Inc. v. SIGA Technologies, Inc., C.A. No. 2627-N. In its amended complaint, PharmAthene asked the Court to order the Company to enter into a license agreement with PharmAthene with respect to ST-246, now also known as Arestvyr, to declare that the Company is obliged to execute such a license agreement, and to award damages resulting from the Company’s supposed breach of that obligation. PharmAthene also alleged that the Company breached an obligation to negotiate such a license agreement in good faith, and sought damages for promissory estoppel and unjust enrichment based on supposed information, capital, and assistance that PharmAthene allegedly provided to the Company during the negotiation process. The Court tried the case in January 2011.
	In September 2011, the Court issued its post-trial opinion. The Court denied PharmAthene’s requests for specific performance and expectation damages measured by the present value of estimated future profits. Nevertheless, the Court held that the Company breached its duty to negotiate in good faith and was liable under the doctrine of promissory estoppel. The Court consequently awarded to PharmAthene what the Court described as an equitable payment stream or equitable lien consisting of fifty percent of the net profits that the Company achieves from sales of ST-246 after the Company secures $40 million in net profits, for ten years following the first commercial sale. In addition, the Court awarded PharmAthene one-third of its reasonable attorneys’ fees and expert witness expenses.
	In May 2012, the Court entered its final order and judgment in this matter, implementing its post-trial opinion. Among other things, the final order and judgment provided that (a) net profits would be calculated in accordance with generally accepted accounting principles applied consistently with how they are applied in the preparation of the Company’s financial statements, (b) the net profits calculation would take into account expenses relating to ST-246 commencing with the Company’s acquisition of ST-246 in August 2004, and (c) PharmAthene could recover $2.4 million of attorneys’ fees and expenses. As of December 31, 2013, SIGA has recorded a $2.6 million loss contingency with respect to the fee, expense and interest portion of the judgment.
	In June 2012, the Company appealed to the Supreme Court of the State of Delaware the final order and judgment and certain earlier rulings of the Court of Chancery. Shortly thereafter, PharmAthene filed its cross-appeal. The Company obtained a stay of enforcement of the fee and expense portion of the judgment by filing a surety bond for the amount of the judgment plus post-judgment interest. The Company posted $1.3 million as collateral for the surety bond which is recorded in other assets as of December 31, 2013. The parties briefed the issues, and argued before the Delaware Supreme Court,en banc, on January 10, 2013.
	On May 24, 2013, the Supreme Court of Delaware issued its decision, affirming the Delaware Court of Chancery’s judgment in part, reversing it in part, and remanding to Vice Chancellor Parsons. The Supreme Court affirmed the Chancery Court determination that the Company had breached its contractual obligation to negotiate in good faith; reversed the promissory estoppel holding; and, reversed the Vice Chancellor’s equitable damages award. The Supreme Court held that the trial judge may award expectation damages for breach of the contractual duty to negotiate in good faith if such damages are proven with reasonable certainty, and remanded to the Chancery Court for consideration of damages consistent with that holding. The Supreme Court also reversed the Chancery Court’s award of attorney fees and expert witness fees because they were predicated in part on a now-reversed finding of liability on PharmAthene’s promissory estoppel claim. The Supreme Court held that the Chancery Court could reevaluate on remand an alternative award, if any, of attorneys’ fees and expert testimony expenses consistent with the Supreme Court’s opinion. Finally, the Supreme Court declined to consider all claims raised in PharmAthene’s cross-appeal because it affirmed the Chancery Court’s finding that the Company was liable for breaching its contractual obligation to negotiate in good faith. On June 11, 2013, the Supreme Court issued its mandate to the Court of Chancery with the decision described above.
	On June 26, 2013, the parties appeared before Vice Chancellor Parsons to discuss the remand, at which time PharmAthene declared its desire to supplement the record with further evidence. Following briefing and argument on August 15, 2013, the Chancery Court granted PharmAthene’s motion to supplement the record and also allowed the Company to submit responsive evidence. On December 18-19, 2013, the Court held an evidentiary hearing with respect to that evidence. On January 15, 2014, after briefing on relevant issues, the parties appeared for oral argument regarding what if any remedy the Chancery Court should impose in light of the remand by the Supreme Court of Delaware.
	No assurances can be given as to the Chancery Court’s determinations on remand.
	From time to time, the Company is involved in disputes or legal proceedings arising in the ordinary course of business. The Company believes that there is no dispute or litigation pending, except as discussed above, that could have, individually or in the aggregate, a material adverse effect on its financial position, results of operations or cash flows.

Financial_Information_by_Quart

Financial Information by Quarter (Unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information [Abstract]	'
Quarterly Financial Information	'
	Financial Information By Quarter (Unaudited)
		Three Months Ended
	2013	31-Mar			30-Jun			30-Sep			31-Dec
		(in thousands, except for per share data)
	Revenues	$	1,328		$	965		$	2,292		$	934
	Selling, general and administrative	3,031			3,166			3,266			3,782
	Research and development	3,645			3,131			4,261			2,819
	Patent preparation fees	458			301			329			333
	Restructuring charges	—			—			—			513
	Operating loss	(5,807		)	(5,633		)	(5,564		)	(6,513		)
	Net loss	(4,876		)	(3,061		)	(4,902		)	(4,338		)
	Earnings (loss) per share: basic and diluted	$	(0.09	)	$	(0.06	)	$	(0.09	)	$	(0.08	)
		Three Months Ended
	2012	31-Mar			30-Jun			30-Sep			31-Dec
		(in thousands, except for per share data)
	Revenues	$	1,466		$	2,701		$	2,290		$	2,514
	Selling, general and administrative	2,214			3,475			3,139			2,583
	Research and development	4,465			5,183			4,170			4,396
	Patent preparation fees	336			376			377			794
	Operating loss	(5,549		)	(6,332		)	(5,396		)	(5,259		)
	Net loss	(4,616		)	(3,767		)	(3,059		)	(2,618		)
	Earnings (loss) per share: basic and diluted	$	(0.09	)	$	(0.07	)	$	(0.06	)	$	(0.04	)

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Use of Estimates	'
	Use of Estimates
	The consolidated financial statements and related disclosures are prepared in conformity with accounting principles generally accepted in the United States of America. Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the period reported. The most significant estimates include the variables used in the calculation of fair value of stock-based awards including options and warrants granted or issued by the Company; reported amounts of revenue and expenses; impairment of goodwill; and the realization of deferred tax assets. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the financial statements in the period they are determined to be necessary. Actual results could differ from these estimates.
Cash, Cash Equivalents, and Short-term Investments and Marketable Securities, Policy	'
	Cash Equivalents, Short-term Investments and Marketable Securities
	The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Highly liquid investments with maturities greater than three months and less than one year are classified as short-term investments. Such investments are generally money market funds, bank certificates of deposit, and U.S. Treasury bills.
	The Company classifies short-term investments and marketable securities with readily determinable fair values as “available-for-sale.” Investments in securities that are classified as available-for-sale are measured at fair market value in the balance sheet and unrealized holding gains and losses on investments are reported as a separate component of stockholders’ equity until realized.
Concentration of Credit Risk, Policy	'
	Concentration of Credit Risk
	The Company has cash in bank accounts that exceed the Federal Deposit Insurance Corporation insured limits. The Company has not experienced any losses on its cash accounts and no allowance has been provided for potential credit losses because management believes that any such losses would be minimal, if any.
Accounts Receivable, Policy	'
	Accounts Receivable
	Accounts receivable are recorded net of provisions for doubtful accounts. At December 31, 2013 and 2012, 100% of accounts receivables represented receivables from National Institutes of Health (“NIH”) and Biomedical Advanced Research and Development Authority (“BARDA”). An allowance for doubtful accounts is based on specific analysis of the receivables. At December 31, 2013 and 2012, the Company had no allowance for doubtful accounts.
Inventory, Policy	'
	Inventory
	Inventories are stated at the lower of cost or estimated realizable value. The Company capitalizes inventory costs associated with the Company’s products when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. Inventory is evaluated for impairment periodically to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value. If certain batches or units of product no longer meet quality specifications or become obsolete due to expiration, the Company records a charge to write down such unmarketable inventory to its estimated realizable value.
Property, Plant and Equipment, Policy	'
	Property, Plant and Equipment
	Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation is provided on a straight-line method over the estimated useful lives of the various asset classes. The estimated useful lives are as follows: 5 years for laboratory equipment; 3 years for computer equipment; and 7 years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the estimated useful lives of the assets or the lease term. Maintenance, repairs and minor replacements are charged to expense as incurred.
Revenue Recognition, Policy	'
	Revenue Recognition
	Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, collectability is reasonably assured, title and risk of loss have been transferred to the customer and there are no further contractual obligations.
	Certain arrangements may provide for multiple deliverables, in which there may be a combination of: up-front licenses; research, development, regulatory or other services; and delivery of product. Multiple deliverable arrangements can be divided into separate units of accounting if the deliverables in the arrangement meet the following criteria: (i) the delivered item(s) have value to the customer on a standalone basis and (ii) in circumstances in which an arrangement includes a general right of return with respect to delivered items, then performance of the remaining deliverables must be considered probable and substantially in control of the Company. If multiple deliverables cannot be divided into separate units of accounting then the deliverables must be combined into a single unit of accounting.
	Total consideration in a multiple deliverable arrangement is allocated to units of accounting on a relative fair value of selling price basis. Consideration allocated to a delivered item or unit of accounting is limited to the amount that is not contingent upon delivery of additional items.
	Direct costs incurred by the Company and associated with the deferral of revenue for a unit of accounting will also be deferred and will be recognized as expenses over the same period that the related deferred revenue is recognized as revenue.
	Subject to the above, payments for development activities are recognized as revenue as earned, over the period of effort. Funding for the acquisition of capital assets under cost-plus-fee contracts or grants is evaluated for appropriate recognition as a reduction to the cost of the asset, a financing arrangement, or revenue based on the specific terms of the related grant or contract.
	For the years ended December 31, 2013, 2012, and 2011, revenues from NIH and BARDA were 100%, 100% and 96%, respectively, of total revenues recognized by the Company.
Research and Development Expense, Policy	'
	Research and Development
	Research and development expenses include costs directly attributable to the conduct of research and development programs, including employee related costs, materials, supplies, depreciation on and maintenance of research equipment, the cost of services provided by outside contractors, including services related to the Company’s clinical trials and facility costs, such as rent, utilities, and general support services. All costs associated with research and development are expensed as incurred. Costs related to the acquisition of technology rights, for which development work is still in process, and that have no alternative future uses, are expensed as incurred.
Goodwill, Policy	'
	Goodwill
	The Company evaluates goodwill for impairment at least annually or as circumstances warrant. The impairment review process compares the fair value of the reporting unit in which goodwill resides to its carrying value. The Company operates as one business and one reporting unit. Therefore, the goodwill impairment analysis is performed on the basis of the Company as a whole, using the market capitalization of the Company as an estimate of its fair value.
Share-based Compensation, Policy	'
	Share-based Compensation
	Stock-based compensation expense for all share-based payment awards made to employees and directors is determined on the grant date; for options awards, fair value is estimated using the Black-Scholes model and for stock appreciation rights (“SARs”), fair value is estimated using a Monte Carlo method. The value of the portion of the award that is ultimately expected to vest is recorded as expense over the requisite service periods in the Company’s consolidated statement of operations.
	These compensation costs are recognized net of an estimated forfeiture rate over the requisite service periods of the awards. Forfeitures are estimated on the date of the respective grant and revised if actual or expected forfeiture activity differs from original estimates.
Income Tax, Policy	'
	Income Taxes
	The Company recognizes income taxes utilizing the asset and liability method of accounting for income taxes. Under this method, deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities at enacted tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is established if it is more likely than not that some or the entire deferred tax asset will not be realized. The recognition of a valuation allowance for deferred taxes requires management to make estimates and judgments about the Company’s future profitability which are inherently uncertain.
Net Loss Per Share, Policy	'
	Net Loss per Share
	The objective of basic earning per share (“EPS”) is to measure the performance of an entity over the reporting period by dividing income (loss) by the weighted average shares outstanding. The objective of diluted EPS is consistent with that of basic EPS, except that it also gives effect to all potentially dilutive common shares outstanding during the period.
	The following is a reconciliation of the basic and diluted net income (loss) per share computation:
		Year Ended December 31,
		2013				2012			2011
	Net (loss) income for basic EPS	$	(17,177,333	)		$	(14,059,539	)	$	29,099,579
	Change in fair value of warrants	—				—			24,436,309
	Net loss (income) for diluted EPS	$	(17,177,333	)		$	(14,059,539	)	$	4,663,270
	Weighted-average shares: basic	52,368,842				51,639,622			50,929,491
	Effect of potential common shares	—				—			3,132,159
	Weighted-average shares: diluted	52,368,842				51,639,622			54,061,650
	Earnings (loss) per share: basic	$	(0.33	)		$	(0.27	)	$	0.57
	Earnings (loss) per share: diluted	$	(0.33	)		$	(0.27	)	$	0.09
	Anti-dilutive employee share-based awards, excluded	—				—			504,668
	The diluted earnings per share calculation reflects the effect of the assumed exercise of outstanding warrants and any corresponding elimination of the benefit included in operating results from the change in fair value of the warrants. Diluted shares outstanding include the dilutive effect of in-the-money options and warrants, unvested restricted stock and restricted stock units. The dilutive effect of such equity awards is calculated based on the average share price for each fiscal period using the treasury stock method. Under the treasury stock method, the amount the employee must pay for exercising stock options, the average amount of compensation cost for future service that the Company has not yet recognized, and the amount of tax benefits that would be recorded in additional paid-in capital when the award becomes deductible, are collectively assumed to be used to repurchase shares.
	The Company incurred losses for the years ended December 31, 2013 and 2012 whereas for the year ended December 31, 2011, the Company had net income. For all periods presented, certain equity instruments are excluded from the calculation of diluted earnings (loss) per share as the effect of such shares is anti-dilutive. The weighted average number of equity instruments excluded consist of:
		Year Ended December 31,
		2013			2012			2011
	Stock Options	2,725,632			2,865,861			504,668
	Stock-Settled Stock Appreciation Rights	439,056			421,020			—
	Restricted Stock Units	981,645			351,011			—
	Warrants	1,802,820			2,263,538			—
	As discussed in Note 5, the appreciation of each SSAR was capped at a determined maximum value. As a result, the weighted average number shown in the table above for stock-settled stock appreciation rights reflects the weighted average maximum number of shares that could be issued.
Fair Value of Financial Instruments, Policy	'
	Fair Value of Financial Instruments
	The carrying value of cash and cash equivalents, accounts payable and accrued expenses approximates fair value due to the relatively short maturity of these instruments. Common stock warrants which are classified as liabilities are recorded at their fair market value as of each reporting period.
	The measurement of fair value requires the use of techniques based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. The inputs create the following fair value hierarchy:
	•	Level 1 – Quoted prices for identical instruments in active markets.
	•	Level 2 – Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.
	•	Level 3 – Instruments where significant value drivers are unobservable to third parties.
	The Company uses model-derived valuations where inputs are observable in active markets to determine the fair value of certain common stock warrants on a recurring basis and classify such warrants in Level 2. The Company utilizes the Black-Scholes model consisting of the following variables: (i) the closing price of SIGA’s common stock; (ii) the expected remaining life of the warrant; (iii) the expected volatility using a weighted-average of historical volatilities from a combination of SIGA and comparable companies; and (iv) the risk-free market rate. At December 31, 2013 and 2012, the fair value of such warrants was as follows:
			2013				2012
	Common stock warrants, current		$	313,425			$	333,793
	Common stock warrants, non-current		—				657,246
			$	313,425			$	991,039
	As of December 31, 2013 and 2012, the Company had $4.0 million and $5.0 million outstanding, respectively, from a loan entered into on December 31, 2012 (refer to Note 6 for details). The fair value of the loan, which is measured using Level 2 inputs, approximates book value at December 31, 2013 and 2012.
	For the years ended December 31, 2013 and 2012, SIGA did not hold any Level 3 securities.
Legal Contingencies, Policy	'
	Legal Contingencies
	The Company is subject to certain contingencies arising in the ordinary course of business. The Company records accruals for these contingencies to the extent that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, that amount is accrued. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, the lowest amount in the range is accrued. We record anticipated recoveries under existing insurance contracts when recovery is assured.
Segment Reporting, Policy	'
	Segment Information
	The Company is managed and operated as one business. The entire business is managed by a single management team that reports to the chief executive officer. The Company does not operate separate lines of business or separate business entities with respect to any of its product candidates. Accordingly, the Company does not prepare discrete financial information with respect to separate product areas or by location and only has one reportable segment.
Recent Accounting Pronouncements, Policy	'
	Recent Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board (“FASB”) issued new guidance on the reporting of reclassifications from accumulated other comprehensive income to net income. The new guidance does not change the requirements for reporting net income or other comprehensive income in financial statements but requires disclosures regarding the reclassification of accumulated other comprehensive income by component into net income. The Company’s adoption of this guidance on January 2, 2013 did not have a material effect on our financial statements.
	In July 2013, the FASB issued new guidance on the financial statement presentation of unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The new guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company does not anticipate a material impact to the Company’s financial position, results of operations or cash flows as a result of this change.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Schedule of earnings per share reconciliation	'
	The following is a reconciliation of the basic and diluted net income (loss) per share computation:
		Year Ended December 31,
		2013				2012			2011
	Net (loss) income for basic EPS	$	(17,177,333	)		$	(14,059,539	)	$	29,099,579
	Change in fair value of warrants	—				—			24,436,309
	Net loss (income) for diluted EPS	$	(17,177,333	)		$	(14,059,539	)	$	4,663,270
	Weighted-average shares: basic	52,368,842				51,639,622			50,929,491
	Effect of potential common shares	—				—			3,132,159
	Weighted-average shares: diluted	52,368,842				51,639,622			54,061,650
	Earnings (loss) per share: basic	$	(0.33	)		$	(0.27	)	$	0.57
	Earnings (loss) per share: diluted	$	(0.33	)		$	(0.27	)	$	0.09
	Anti-dilutive employee share-based awards, excluded	—				—			504,668
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	'
	The Company incurred losses for the years ended December 31, 2013 and 2012 whereas for the year ended December 31, 2011, the Company had net income. For all periods presented, certain equity instruments are excluded from the calculation of diluted earnings (loss) per share as the effect of such shares is anti-dilutive. The weighted average number of equity instruments excluded consist of:
		Year Ended December 31,
		2013			2012			2011
	Stock Options	2,725,632			2,865,861			504,668
	Stock-Settled Stock Appreciation Rights	439,056			421,020			—
	Restricted Stock Units	981,645			351,011			—
	Warrants	1,802,820			2,263,538			—
Fair Value Measurements, Recurring and Nonrecurring	'
	At December 31, 2013 and 2012, the fair value of such warrants was as follows:
			2013				2012
	Common stock warrants, current		$	313,425			$	333,793
	Common stock warrants, non-current		—				657,246
			$	313,425			$	991,039

Stock_Compensation_Plans_Table

Stock Compensation Plans (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock options, valuation assumptions	'
	The fair value of option grants were estimated at the date of grant during the years ended December 31, 2013, 2012, and 2011 based upon the following range of assumptions:
		2013			2012		2011
	Expected volatility	67	%		77	%	76	%
	Expected dividend yield	—	%		—	%	—	%
	Risk-free interest rate	0.84% - 1.29%			0.98% - 1.24%		1.94	%
	Expected life	6 years			6 years		6 years
Stock appreciations rights, valuation assumptions	'
	The fair value of granted SSARs has been estimated utilizing a Monte Carlo method. The Monte Carlo method is a statistical simulation technique used to provide the grant-date fair value of an award. As the issued SSARs were capped at maximum values, such attribute was considered in the simulation. The following table presents the weighted-average assumptions utilized in the valuations:
			2012
	Expected volatility		71	%
	Expected life from grant date		4.5 years
	Expected dividend yield		—	%
	Risk-free interest rate		0.61	%
Stock options activity	'
	A summary of the Company’s stock option activity is as follows:
		Number of			Weighted			Weighted	Aggregate
		Options			Average Exercise			Average	Intrinsic Value
					Price			Remaining Life	(in thousands)
								(in years)
	Outstanding at January 1, 2013	2,902,708			$	4.28
	Granted	27,000			3.87
	Exercised	(506,623	)		1.37
	Canceled/Expired	(69,455	)		4.06
	Outstanding at December 31, 2013	2,353,630			$	4.91		5.09	$	849,950
	Vested and expected to vest at December 31, 2013	2,343,414			$	4.91		5.1	$	844,331
	Exercisable at December 31, 2013	2,013,960			$	5.09		4.99	$	663,128
Stock appreciation rights award activity	'
	A summary of the Company’s SSAR activity is as follows:
		Number of			Weighted			Weighted	Aggregate
		SSARs			Average Exercise			Average	Intrinsic Value
					Price			Remaining Life	(in thousands)
								(in years)
	Outstanding at January 1, 2013	1,420,951			$	3.53
	Granted	—			—
	Exercised	(8,750	)		3.53
	Canceled/Expired	(101,301	)		3.53
	Outstanding at December 31, 2013	1,310,900			$	3.53		5.09	$	—
	Vested and expected to vest at December 31, 2013	1,285,297			$	3.53		5.09	$	—
	Exercisable at December 31, 2013	459,684			$	3.53		5.09	$	—
Restricted stock and restricted stock units activity	'
	RSUs awarded to employees vest in equal annual installments over a three-year period and RSUs awarded to directors of the Company vest over a one-year period. A summary of the Company’s RSU activity is as follows:
		Number of			Weighted
		RSUs			Average Grant-Date Fair Value
	Outstanding at January 1, 2013	460,000			$	2.82
	Granted	775,000			2.98
	Vested	(253,332	)		2.69
	Canceled/Expired	(15,000	)		2.82
	Outstanding at December 31, 2013	966,668			$	2.98
Warrants activity	'
	A summary of the Company’s warrant activity is as follows:
		Number of			Weighted Average
		Warrants			Exercise Price
	Outstanding at January 1, 2013	2,253,902			$	3.3
	Granted	250,000			3.29
	Exercised	(815,568	)		2.92
	Canceled/Expired	(472,108	)		3.81
	Outstanding at December 31, 2013	1,216,226			$	3.36

Debt_Tables

Debt (Tables)	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Debt principal payments	'
	The aggregate amount of required principal payments at December 31, 2013 are as follows:
	2014	$	2,000,000
	2015	2,000,000
	Unamortized discount	(41,226		)
	Total	$	3,958,774

Inventory_Inventory_Tables

Inventory Inventory (Tables)	12 Months Ended
	Dec. 31, 2013
Inventory [Abstract]	'
Inventory	'
	Inventory consisted of the following at December 31, 2013 and 2012:
		2013		2012
	Work in-process	$	6,152,198	$	17,641,922
	Finished goods	14,363,151		—
	Inventory	$	20,515,349	$	17,641,922

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, plant and equipment	'
	Property, plant and equipment consisted of the following at December 31, 2013 and 2012:
		2013			2012
	Laboratory equipment	$	2,473,428		$	2,305,410
	Leasehold improvements	3,166,622			2,817,123
	Computer equipment	655,364			458,421
	Furniture and fixtures	488,168			345,287
		6,783,582			5,926,241
	Less - accumulated depreciation	(5,401,509		)	(4,938,372		)
	Property, plant and equipment, net	$	1,382,073		$	987,869

Accrued_Expenses_and_Other_Cur1

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Accrued Expenses and Other Current Liabilities	'
	Accrued expenses and other current liabilities consisted of the following at December 31, 2013 and 2012:
		2013		2012
	Loss contingency	$	2,635,270	$	2,491,981
	Bonus	—		250,000
	Professional fees	794,275		579,609
	Vacation	252,410		328,463
	Other	1,160,438		633,796
	Accrued expenses and other current liabilities	$	4,842,393	$	4,283,849

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of components of income tax expense (benefit)	'
	At December 31, 2013 and 2012, the Company's provision (benefit) for income taxes is comprised of the following:
		2013				2012				2011
	Current:
	Federal	$	1,608,033			$	—			$	—
	State and local	373,455				3,649				20,332
	Total current provision (benefit)	1,981,488				3,649				20,332
	Deferred:
	Federal	(10,072,499		)		(7,557,163		)		(35,493,317		)
	State and local	472,572				(290,639		)		(558,661		)
	Total deferred provision (benefit)	(9,599,927		)		(7,847,802		)		(36,051,978		)
	Total provision (benefit)	$	(7,618,439	)		$	(7,844,153	)		$	(36,031,646	)
Schedule of deferred tax assets and liabilities	'
	At December 31, 2013 and 2012, the Company’s deferred tax assets and liabilities are comprised of the following:
		2013				2012
	Deferred income tax assets:
	Net operating losses	$	7,750,690			$	36,764,901
	Deferred research and development costs	2,278,397				2,950,555
	Amortization of intangible assets	1,342,555				1,572,281
	Share-based compensation	2,166,125				1,768,990
	Depreciation	604,973				709,184
	Deferred revenue	48,685,086				4,403,266
	Alternative minimum tax credits	1,608,033				—
	Loss contingency	942,529				892,129
	Other	554,777				212,483
	Deferred income tax assets	65,933,165				49,273,789
	Less: valuation allowance	(4,442,929		)		(4,328,233		)
	Deferred income tax assets, net of valuation allowance	$	61,490,236			$	44,945,556
	Deferred income tax liabilities:
	Amortization of goodwill	(224,908		)		(203,682		)
	Capitalized contract costs	(7,940,796		)		(1,017,269		)
	Deferred income tax assets, net	$	53,324,532			$	43,724,605
Schedule of effective income tax rate reconciliation	'
	The Company’s effective tax rate differs from the U.S. Federal Statutory income tax rate of 35% as follows:
		2013			2012			2011
	Statutory federal income tax rate	(35.0	)%		(35.0	)%		(35.0	)%
	State tax benefit	2.9	%		(1.4	)%		0.3	%
	Gain (loss) from fair value of common warrants	0.1	%		(1.3	)%		(123.4	)%
	Share-based compensation	0.4	%		0.8	%		24.8	%
	Other	0.3	%		0.5	%		1.4	%
	Valuation allowance on deferred tax assets	0.6	%		0.5	%		(387.6	)%
	Effective tax rate	(30.7	)%		(35.9	)%		(519.5	)%

Restructuring_charges_Tables

Restructuring charges (Tables)	12 Months Ended
	Dec. 31, 2013
Restructuring Charges [Abstract]	'
Restructuring and related costs	'
		Accrued as of January 1, 2013		Charges		Payments			Non-Cash Items			Accrued as of December 31, 2013
	Severance Charges	$	—	$	324,615	$	(206,385	)	$	—		$	118,230
	Asset Impairments	—		188,329		—			(188,329		)	—
		$	—	$	512,944	$	(206,385	)	$	(188,329	)	$	118,230

Commitments_and_Contingencies_

Commitments and Contingencies Operating Lease Commitments (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases	'
	Future minimum rental commitments under non-cancelable operating leases as of December 31, 2013 are expected to be as follows:
	2014	$	1,602,840
	2015	1,622,508
	2016	1,642,176
	2017	1,661,844
	2018	734,360
	Thereafter	1,268,440
	Total	$	8,532,168

Financial_Information_by_Quart1

Financial Information by Quarter (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information [Abstract]	'
Schedule of quarterly financial information	'
	Financial Information By Quarter (Unaudited)
		Three Months Ended
	2013	31-Mar			30-Jun			30-Sep			31-Dec
		(in thousands, except for per share data)
	Revenues	$	1,328		$	965		$	2,292		$	934
	Selling, general and administrative	3,031			3,166			3,266			3,782
	Research and development	3,645			3,131			4,261			2,819
	Patent preparation fees	458			301			329			333
	Restructuring charges	—			—			—			513
	Operating loss	(5,807		)	(5,633		)	(5,564		)	(6,513		)
	Net loss	(4,876		)	(3,061		)	(4,902		)	(4,338		)
	Earnings (loss) per share: basic and diluted	$	(0.09	)	$	(0.06	)	$	(0.09	)	$	(0.08	)
		Three Months Ended
	2012	31-Mar			30-Jun			30-Sep			31-Dec
		(in thousands, except for per share data)
	Revenues	$	1,466		$	2,701		$	2,290		$	2,514
	Selling, general and administrative	2,214			3,475			3,139			2,583
	Research and development	4,465			5,183			4,170			4,396
	Patent preparation fees	336			376			377			794
	Operating loss	(5,549		)	(6,332		)	(5,396		)	(5,259		)
	Net loss	(4,616		)	(3,767		)	(3,059		)	(2,618		)
	Earnings (loss) per share: basic and diluted	$	(0.09	)	$	(0.07	)	$	(0.06	)	$	(0.04	)

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Accounts Receivable, Property, Plant and Equipment, and Net Loss Per Share) (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accounting Policies [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Receivables Percentage	100.00%	'	'	'	100.00%	'	'	'	100.00%	100.00%	'
Net loss per share [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Net income (loss)	($4,338,000)	($4,902,000)	($3,061,000)	($4,876,000)	($2,618,000)	($3,059,000)	($3,767,000)	($4,616,000)	($17,177,333)	($14,059,539)	$29,099,579
Change in fair value of warrants	'	'	'	'	'	'	'	'	0	0	-24,436,309
Net loss (income) for diluted EPS	'	'	'	'	'	'	'	'	($17,177,333)	($14,059,539)	$4,663,270
Weighted average shares: basic	'	'	'	'	'	'	'	'	52,368,842	51,639,622	50,929,491
Effect of potential common shares	'	'	'	'	'	'	'	'	0	0	3,132,159
Weighted-average shares: diluted	'	'	'	'	'	'	'	'	52,368,842	51,639,622	54,061,650
Earning (loss) per share: basic	'	'	'	'	'	'	'	'	($0.33)	($0.27)	$0.57
Earnings (loss) per share: diluted	'	'	'	'	'	'	'	'	($0.33)	($0.27)	$0.09
Anti-dilutive employee share-based awards, excluded	'	'	'	'	'	'	'	'	0	0	504,668
Lab equipment [Member]	'	'	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Property, plant and equipment, useful life	'	'	'	'	'	'	'	'	'5 years	'	'
Computer Equipment [Member]	'	'	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Property, plant and equipment, useful life	'	'	'	'	'	'	'	'	'3 years	'	'
Furniture and Fixtures [Member]	'	'	'	'	'	'	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Property, plant and equipment, useful life	'	'	'	'	'	'	'	'	'7 years	'	'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Anti-dilutive Securities Exluded from Calculation of Diluted Loss per Share) (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive employee share-based awards, excluded	0	0	504,668
Stock Options	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive employee share-based awards, excluded	2,725,632	2,865,861	504,668
Stock Appreciation Rights (SARs) [Member]	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive employee share-based awards, excluded	439,056	421,020	0
Restricted Stock Units (RSUs)	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive employee share-based awards, excluded	981,645	351,011	0
Warrants	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'
Anti-dilutive employee share-based awards, excluded	1,802,820	2,263,538	0

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Fair Value of Financial Instruments) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Common stock warrants, current	$313,425	$333,793
Common stock warrants, noncurrent	0	657,246
Term loan	4,000,000	5,000,000
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Common stock warrants, current	313,425	333,793
Common stock warrants, noncurrent	0	657,246
Common stock warrants, current and noncurrent	$313,425	$991,039

Summary_of_Significant_Account6

Summary of Significant Accounting Policies Revenue (Details) (BARDA Contract)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
BARDA Contract	'	'	'
Revenue [Line Items]	'	'	'
Concentration risk, percentage	100.00%	100.00%	96.00%

Procurement_Contract_and_Resea1

Procurement Contract and Research Agreements (Details) (USD $)	0 Months Ended	1 Months Ended		3 Months Ended				6 Months Ended	12 Months Ended
	Jun. 24, 2011	Feb. 28, 2014	31-May-11	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jun. 30, 2013	Dec. 31, 2013
	course	course	course	course	course				course
Procurement Contract [Line Items]	'	'	'	'	'	'	'	'	'
Deferred costs	'	'	'	'	$22,583,202	$2,841,534	'	'	$22,583,202
Research and development revenue long-term contract	'	'	'	'	'	'	'	'	1,200,000
Contract receivable collected for reimbursed R&D and supportive studies	'	'	'	'	5,400,000	'	'	'	5,400,000
Number of active contracts	'	'	'	'	'	'	'	'	1
Number of active grants	'	'	'	'	'	'	'	'	2
Potential future research and development funding	'	'	'	'	13,900,000	'	'	'	13,900,000
BARDA Contract	'	'	'	'	'	'	'	'	'
Procurement Contract [Line Items]	'	'	'	'	'	'	'	'	'
Number of courses to be delivered	'	'	2,000,000	'	'	'	'	'	'
Value of contract	'	'	463,000,000	'	'	'	'	'	'
Contract value of development and support activities	'	'	54,000,000	'	'	'	'	'	'
Option to purchase additional courses	'	'	12,000,000	'	'	'	'	'	'
Number of courses under modified contract	1,700,000	'	'	'	'	'	'	'	'
Number of courses manufactured using federal funds	300,000	'	'	'	'	'	'	'	'
Proceeds from advance payments under the BARDA contract	'	'	'	'	'	'	41,000,000	'	'
Deferred costs	'	'	'	'	22,600,000	2,800,000	'	'	22,600,000
Deferred revenue	'	'	'	'	'	'	'	'	162,200,000
Milestone payment	'	'	'	'	'	12,300,000	'	8,200,000	'
Contract receivable collected	'	'	'	'	101,500,000	'	'	'	101,500,000
Contract receivable collected, delivered products	'	'	'	$25,000,000	$96,100,000	'	'	'	$96,100,000
Government Contract, number of courses delivered	'	256,000	'	192,000	'	'	'	'	725,000
Government Contract, number of courses delivered at no cost	'	'	'	'	'	'	'	'	195,000
Government Contract, number of courses accepted at no cost	'	'	'	133,000	62,000	'	'	'	'

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	12 Months Ended				0 Months Ended		12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2006	Apr. 30, 2013	Jun. 18, 2010	Dec. 31, 2009	Jun. 19, 2008	Jun. 19, 2008	Dec. 31, 2013	Dec. 31, 2012
					Affiliated Entity	Affiliated Entity	Affiliated Entity	Affiliated Entity	Extended Expiration Period [Member]	Fair Value, Measurements, Recurring [Member]	Fair Value, Measurements, Recurring [Member]
									Affiliated Entity	Fair Value, Inputs, Level 2 [Member]	Fair Value, Inputs, Level 2 [Member]
Equity [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Capital units, authorized	110,000,000	'	'	'	'	'	'	'	'	'	'
Common stock, shares authorized	100,000,000	100,000,000	'	'	'	'	'	'	'	'	'
Preferred stock, shares authorized	10,000,000	'	'	'	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Common stock warrants, current	$313,425	$333,793	'	'	'	'	'	'	'	$313,425	$333,793
Common stock warrants, current and noncurrent	'	'	'	'	'	'	'	'	'	313,425	991,039
Change In fair value of common stock warrants	73,756	-804,516	-24,436,309	'	'	'	'	'	'	'	'
Service Agreement Term	'	'	'	'	'3 years	'	'	'	'	'	'
Warrants to purchase common stock	'	'	'	1,000,000	250,000	718,954	326,797	'	238,000	'	'
Exercise price of warrants to purchase common stock	'	'	'	4.99	3.29	3.519	3.519	'	3.06	'	'
Warrants contractual term (in years)	'	'	'	'	'2 years	'4 years	'4 years	'	'	'	'
Commitment to Invest	'	'	'	'	'	'	'	8,000,000	'	'	'
Warrants to purchase percentage of acquired shares	'	'	'	'	'	'	'	40.00%	'	'	'
Proceeds from issuance of warrants and options	'	'	'	'	'	$5,500,000	$2,500,000	'	'	'	'
Common stock, shares issued	53,108,844	51,642,520	'	'	'	1,797,386	816,993	'	'	'	'

Stock_Compensation_Plans_Stock

Stock Compensation Plans (Stock Plans and Stock Options) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Apr. 25, 2012	31-May-10
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Number of shares authorized	'	'	'	4,500,000	2,000,000
Stock-based compensation expense	$2,300,000	$1,800,000	$12,500,000	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'	'	'	'	'
Number of shares outstanding at beginning of period	2,902,708	'	'	'	'
Number of shares granted	27,000	'	'	'	'
Number of shares exercised	-506,623	'	'	'	'
Number of shares canceled and expired	-69,455	'	'	'	'
Number of shares outstanding at end of period	2,353,630	2,902,708	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]	'	'	'	'	'
Weighted average remaining life, outstanding	'5 years 1 month 3 days	'	'	'	'
Intrinsic value, outstanding	849,950	'	'	'	'
Number of shares vested and expected to vest	2,343,414	'	'	'	'
Weighted average exercise price, vested and expected to vest	$4.91	'	'	'	'
Weighted average remaining life, vested and expected to vest	'5 years 1 month 7 days	'	'	'	'
Intrinsic value, vested and expected to vest	844,331	'	'	'	'
Number of shares exercisable	2,013,960	'	'	'	'
Weighted average exercise price, exercisable	$5.09	'	'	'	'
Weighted average remaining life, exercisable	'4 years 11 months 28 days	'	'	'	'
Intrinsic value, exercisable	663,128	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$2.34	$1.77	$7.01	'	'
Performance-based stock options	500,000	500,000	'	'	'
Stock Options	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Expected volatility	67.00%	77.00%	76.00%	'	'
Expected dividend yield	0.00%	0.00%	0.00%	'	'
Risk-free interest rate	'	'	1.94%	'	'
Expected life from grant date	'6 years	'6 years	'6 years	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]	'	'	'	'	'
Weighted average exercise price outstanding at beginning of period	$4.28	'	'	'	'
Weighted average exercise price, granted	$3.87	'	'	'	'
Weighted average exercise price, exercised	$1.37	'	'	'	'
Weighted average exercise price, canceled and expired	$4.06	'	'	'	'
Weighted average exercise price outstanding at end of period	$4.91	$4.28	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]	'	'	'	'	'
Unrecognized stock-based compensation cost, net of estimated forfeitures	189,000	'	'	'	'
Weighted average remaining requisite service period (in years)	'1 year 0 months 23 days	'	'	'	'
Fair value of vested stock options	600,000	900,000	2,200,000	'	'
Total intrinsic value of stock options exercised	$959,000	$5,000	$12,346,812	'	'
Stock Options | Minimum [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Risk-free interest rate	0.84%	0.98%	'	'	'
Stock Options | Maximum [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Risk-free interest rate	1.29%	1.24%	'	'	'
Performance Shares [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]	'	'	'	'	'
Performance-based stock options	200,000	'	'	'	'
Performance-based stock options exercisable	300,000	'	'	'	'

Stock_Compensation_Plans_Stock1

Stock Compensation Plans (Stock Appreciation Rights) (Details) (USD $)	6 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2012	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price [Roll Forward]	'	'	'	'	'
Weighted average remaining life, outstanding	'	'	'5 years 1 month 3 days	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]	'	'	'	'	'
Number of shares vested and expected to vest	'	'	2,343,414	'	'
Stock Appreciation Rights (SARs) [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Weighted average grant-date fair value, granted	'	'	'	$0.68	'
Award vesting period	'	'3 years	'	'	'
Maximum number of shares to be issued	'	'	407,705	453,465	'
Expected volatility	71.00%	'	'	'	'
Expected life from grant date	'4 years 6 months	'	'	'	'
Expected dividend yield	0.00%	'	'	'	'
Risk-free interest rate	0.61%	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]	'	'	'	'	'
Number of shares granted	'	'	0	1,446,802	'
Number of shares exercised	'	'	-8,750	'	'
Number of shares canceled and expired	'	'	-101,301	'	'
Number of shares outstanding at end of period	'	'	1,310,900	1,420,951	'
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price [Roll Forward]	'	'	'	'	'
Weighted average exercise price granted	'	'	$0	'	'
Weighted average exercise price exercised	'	'	$3.53	'	'
Weighted average exercise price canceled and expired	'	'	$3.53	'	'
Weighted average exercise price outstanding at end of period	'	'	$3.53	$3.53	'
Weighted average remaining life, outstanding	'	'	'5 years 1 month 1 day	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]	'	'	'	'	'
Intrinsic value outstanding	'	'	$0	'	'
Number of shares vested and expected to vest	'	'	1,285,297	'	'
Weighted average exercise price, vested and expected to vest	'	'	$3.53	'	'
Weighted average remaining life, vested and expected to vest	'	'	'5 years 1 month 1 day	'	'
Intrinsic value, vested and expected to vest	'	'	$0	'	'
Number of shares exercisable	'	'	459,684	'	'
Weighted average exercise price, exercisable	'	'	$3.53	'	'
Weighted average remaining life, exercisable	'	'	'5 years 1 month 1 day	'	'
Intrinsic value, exercisable	'	'	0	'	'
Unrecognized stock-based compensation cost	'	'	302,000	'	'
Weighted average remaining requisite service period	'	'	'1 year 1 month 1 day	'	'
Fair value of vested stock appreciation rights	'	'	317,000	0	0
Total intrinsic value of stock appreciation rights exercised	'	'	$4,000	$0	$0
Maximum [Member] | Stock Appreciation Rights (SARs) [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Expiration period	'	'7 years	'	'	'

Stock_Compensation_Plans_Restr

Stock Compensation Plans (Restricted Stock Awards and Restricted Stock Units) (Details) (Restricted Stock Units (RSUs) [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]	'	'	'
Number of shares granted	775,000	'	'
Number of shares vested	-253,332	'	'
Number of shares canceled and expired	-15,000	'	'
Number of shares outstanding at end of period	966,668	460,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price [Roll Forward]	'	'	'
Weighted average grant-date fair value, granted	$2.98	$2.82	$14.26
Weighted average grant-date fair value, vested	$2.69	'	'
Weighted averaged grant-date fair value, canceled and expired	$2.82	'	'
Weighted average grant-date fair value outstanding at end of period	$2.98	$2.82	'
Unrecognized stock-based compensation cost	$1,734,087	'	'
Weighted average remaining requisite service period	'1 year 7 months 30 days	'	'
Fair value of stock compensation vested	$681,896	$0	$10,000,000
Maximum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Award vesting period	'3 years	'	'
Minimum [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Award vesting period	'1 year	'	'

Stock_Compensation_Plans_Warra

Stock Compensation Plans (Warrants) (Details) (Warrant [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Warrant [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]	'	'
Number of shares granted	250,000	'
Number of shares exercised	-815,568	'
Number of shares canceled and expired	-472,108	'
Number of shares outstanding at end of period	1,216,226	2,253,902
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price [Roll Forward]	'	'
Weighted average exercise price granted	$3.29	'
Weighted average exercise price exercised	$2.92	'
Weighted average exercise price canceled and expired	$3.81	'
Weighted average exercise price outstanding at end of period	$3.36	$3.30

Debt_Details

Debt (Details) (USD $)	3 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Debt Disclosure [Abstract]	'	'
Term loan	$4,000,000	$5,000,000
Term loan, fixed interest rate	'	9.85%
Line of credit facility, maximum borrowing capacity	'	7,000,000
Line of credit facility, interest rate	'	5.25%
Line of credit facility, variable rate basis	'	1.50%
Loan, period	'	'3 years
Line of credit facility, borrowing base percentage	'	85.00%
Term loan, periodic payment of principal	167,000	'
Debt issuance costs	'	386,000
Debt discount	'	90,000
Term loan, principal payments due in 2014	2,000,000	'
Term loan, principal payments due in 2015	2,000,000	'
Unamortized discount	-41,226	'
Total	$3,958,774	'

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	12 Months Ended			12 Months Ended
	Dec. 31, 2013	Feb. 29, 2012	Dec. 01, 2009	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Affiliated Entity	Affiliated Entity	Affiliated Entity	Member of Board of Directors	Member of Board of Directors	Member of Board of Directors
Related Party Transaction [Line Items]	'	'	'	'	'	'
Lease property price per month	'	$12,000	$8,000	'	'	'
Free rent period	'5 months	'	'	'	'	'
Monthly rental payments first five years	60,000	'	'	'	'	'
Initial rent period	'5 years	'	'	'	'	'
Monthly rental payments after five years	63,000	'	'	'	'	'
Rent period after first five years	'2 years	'	'	'	'	'
Legal fees	'	'	'	1,800,000	2,000,000	3,100,000
Accounts payable to related party	'	'	'	$200,000	'	'

Inventory_Details

Inventory (Details) (USD $)	12 Months Ended		12 Months Ended
	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013
			BARDA Contract
			course
Inventory [Line Items]	'	'	'
Number of courses delivered and accepted	'	'	787,000
Work in process	$17,641,922	$6,152,198	'
Finished goods	0	14,363,151	'
Inventory	17,641,922	20,515,349	'
Inventory write-downs	$500,000	'	'

Property_Plant_and_Equipment_D

Property, Plant and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property, Plant and Equipment [Abstract]	'	'	'
Laboratory equipment, gross	$2,473,428	$2,305,410	'
Leasehold improvements, gross	3,166,622	2,817,123	'
Computer equipment, gross	655,364	458,421	'
Furniture and fixtures, gross	488,168	345,287	'
Property, plant and equipment, gross	6,783,582	5,926,241	'
Accumulated depreciation, depletion and amortization, property, plant, and equipment	-5,401,509	-4,938,372	'
Property, plant and equipment, net	1,382,073	987,869	'
Depreciation and other amortization	463,137	419,358	568,288
Property, plant and equipment, disposals	'	'	$25,000

Accrued_Expenses_and_Other_Cur2

Accrued Expenses and Other Current Liabilities (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Payables and Accruals [Abstract]	'	'
Loss contingency	$2,635,270	$2,491,981
Bonus	0	250,000
Professional fees	794,275	579,609
Vacation	252,410	328,463
Other	1,160,438	633,796
Total	$4,842,393	$4,283,849

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]	'	'	'
Current federal tax expense (benefit)	$1,608,033	$0	$0
Current state and local tax expense (benefit)	373,455	3,649	20,332
Current income tax expense (benefit)	1,981,488	3,649	20,332
Deferred federal income tax expense (benefit)	-10,072,499	-7,557,163	-35,493,317
Deferred state and local income tax expense (Benefit)	472,572	-290,639	-558,661
Deferred income tax expense (benefit)	-9,599,927	-7,847,802	-36,051,978
Benefit from (provision for) income taxes	-7,618,439	-7,844,153	-36,031,646
Deferred tax assets:	'	'	'
Deferred tax assets, net operating losses	7,750,690	36,764,901	'
Deferred tax assets, capitalized research and development costs	2,278,397	2,950,555	'
Deferred tax assets, intangible assets	1,342,555	1,572,281	'
Deferred tax assets, share-based compensation cost	2,166,125	1,768,990	'
Deferred tax assets, property, plant and equipment	604,973	709,184	'
Deferred tax assets, deferred income	48,685,086	4,403,266	'
Deferred tax assets, alternative minimum tax	1,608,033	0	'
Deferred tax assets, contingencies	942,529	892,129	'
Deferred tax assets, other	554,777	212,483	'
Deferred tax assets, gross	65,933,165	49,273,789	'
Deferred tax assets, valuation allowance	4,442,929	4,328,233	'
Deferred tax assets, net of valuation allowance	61,490,236	44,945,556	'
Deferred tax liabilities:	'	'	'
Deferred tax liabilities, goodwill	-224,908	-203,682	'
Deferred tax liabilities, capitalized contract costs	-7,940,796	-1,017,269	'
Deferred tax assets, net	53,324,532	43,724,605	'
Federal net operating loss carryforwards	23,500,000	'	'
Operating loss carryforwards, subject to limitations	3,100,000	'	'
Operating loss carryforwards from excess tax deductions on stock option activity	1,600,000	'	'
Federal net operating loss carryforwards, Expired	'	1,200,000	'
Benefit from (provision for) income taxes	($7,618,439)	($7,844,153)	($36,031,646)
Effective Income Tax Rate, Continuing Operations, Tax Rate Reconciliation [Abstract]	'	'	'
U.S. federal statutory taxes	-35.00%	-35.00%	-35.00%
State and local income taxes	2.90%	-1.40%	0.30%
Loss from fair value of common warrants	0.10%	-1.30%	-123.40%
Share-based compensation cost	0.40%	0.80%	24.80%
Other adjustments	0.30%	0.50%	1.40%
Change in deferred tax assets valuation allowance	0.60%	0.50%	-387.60%
Effective income tax rate	-30.70%	-35.90%	-519.50%

Restructuring_charges_Details

Restructuring charges (Details) (USD $)	3 Months Ended				12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Restructuring Charges [Abstract]	'	'	'	'	'	'	'
Restructuring and related cost, expected expense reduction	'	'	'	'	$6,000,000	'	'
Severance costs	'	'	'	'	324,615	'	'
Restructuring costs and asset impairment charges	'	'	'	'	-188,329	'	'
Restructuring charges	513,000	0	0	0	512,944	0	0
Payments for restructuring	'	'	'	'	-206,385	'	'
Accrued severance charges	$118,230	'	'	'	$118,230	'	'

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (License Agreement litigation, Pending litigation, USD $)	1 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2011	Dec. 31, 2013	31-May-12
Loss Contingencies [Line Items]	'	'	'
Percentage of net profits from sales after net profit threshold	'	50.00%	'
Net profit threshold	'	$40	'
Equitable payment stream following first commercial sale, duration	'10 years	'	'
Percentage of litigation costs awarded	33.00%	'	'
Plaintiff attorneys' fee and expenses	'	'	2.4
Accrued liabilities	'	'	'
Loss Contingencies [Line Items]	'	'	'
Accrued liabilities, current	'	2.6	'
Surety bond | Other assets	'	'	'
Loss Contingencies [Line Items]	'	'	'
Payment to post collateral for surety bond	'	$1.30	'

Commitments_and_Contingencies_2

Commitments and Contingencies Operating Leases (Details) (USD $)	3 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Commitments and Contingencies Disclosure [Abstract]	'	'	'	'
Term Extension	'5 years	'	'	'
Rent expense	'	$1,400,000	$1,000,000	$827,000
Operating leases, future minimum payments due, next twelve months	1,602,840	1,602,840	'	'
Operating leases, future minimum payments, due in two years	1,622,508	1,622,508	'	'
Operating leases, future minimum payments, due in three years	1,642,176	1,642,176	'	'
Operating leases, future minimum payments, due in four years	1,661,844	1,661,844	'	'
Operating leases, future minimum payments, due in five years	734,360	734,360	'	'
Operating Leases, future minimum payments, due thereafter	1,268,440	1,268,440	'	'
Operating leases, future minimum payments due	$8,532,168	$8,532,168	'	'

Financial_Information_by_Quart2

Financial Information by Quarter (Unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Research and development	$934,000	$2,292,000	$965,000	$1,328,000	$2,514,000	$2,290,000	$2,701,000	$1,466,000	$5,519,300	$8,970,835	$12,725,792
Selling, general and administrative expense	3,782,000	3,266,000	3,166,000	3,031,000	2,583,000	3,139,000	3,475,000	2,214,000	13,244,819	11,410,131	23,931,713
Research and development expense	2,819,000	4,261,000	3,131,000	3,645,000	4,396,000	4,170,000	5,183,000	4,465,000	13,856,500	18,213,036	18,367,348
Patent preparation fees	333,000	329,000	301,000	458,000	794,000	377,000	376,000	336,000	1,421,218	1,883,405	1,808,168
Restructuring charges	513,000	0	0	0	'	'	'	'	512,944	0	0
Operating loss	-6,513,000	-5,564,000	-5,633,000	-5,807,000	-5,259,000	-5,396,000	-6,332,000	-5,549,000	-23,516,181	-22,535,737	-31,381,437
Net income (loss)	($4,338,000)	($4,902,000)	($3,061,000)	($4,876,000)	($2,618,000)	($3,059,000)	($3,767,000)	($4,616,000)	($17,177,333)	($14,059,539)	$29,099,579
Earning (loss) per share: basic and diluted	($0.08)	($0.09)	($0.06)	($0.09)	($0.04)	($0.06)	($0.07)	($0.09)	'	'	'